Side Effects of Drugs Annual

A worldwide yearly survey of new data in adverse drug reactions
 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 26. November 2015
  • |
  • 692 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-444-63531-0 (ISBN)
 
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions was first published in 1977, and has been continually published as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each Annual provides clinicians and medical investigators with a reliable and critical survey of new data and trends in the area of adverse drug reactions and interactions, with an international team of specialists contributing their expertise each year.
  • Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
  • Authored and reviewed by pioneers throughout the world in the clinical and practice sciences
  • Presents an essential clinical on the side effects of drugs for practitioners and healthcare professionals
0378-6080
  • Englisch
  • Niederlande
Elsevier Science
  • 11,90 MB
978-0-444-63531-0 (9780444635310)
0444635319 (0444635319)
weitere Ausgaben werden ermittelt
  • Front Cover
  • A worldwide yearly survey of new data in adverse drug reactions
  • Copyright
  • Contributors
  • Contents
  • Preface
  • Special Reviews in SEDA 37
  • Table of Essays, Annuals 1-36
  • Abbreviations
  • ADRs, ADEs and SEDs: A Bird's Eye View
  • I. Introduction
  • A. Analysis of ADEs, ADRs, Side Effects and Toxicity
  • B. Terminology
  • C. EIDOS
  • D. DOTS
  • E. WHO Classification
  • References on Adverse Drug Reactions
  • II. PHARMACOGENOMICS Considerations
  • A. Introduction
  • B. The Context of Pharmacogenomics
  • References Pharmacogenomics Considerations
  • III. Immunological Reactions
  • A. Type I Reactions (IgE-Mediated Anaphylaxis
  • Immediate Hypersensitivity)
  • B. Type II Reactions (Cytotoxic Reactions)
  • C. Type III Reactions (Immune Complex Reactions)
  • D. Type IV Reactions (Cell-Mediated or Delayed Hypersensitivity Reactions)
  • E. Other types of reactions
  • References
  • IV. Analysis of Toxicological Reactions
  • A. Potentiation Reactions
  • B. Synergistic Effect
  • C. Additive Effect
  • D. Antagonistic Effects
  • References
  • V. Grades of Adverse Drug Reactions
  • References
  • VI. FDA Pregnancy Categories/Classification of teratogenicity
  • References
  • Conclusion
  • Chapter 1: Central Nervous System Stimulants and Drugs That Suppress Appetite
  • Amphetamine and Amphetamine Derivates [SEDA-15, 180
  • SEDA-32, 1
  • SEDA-33, 1
  • SEDA-34, 1
  • SEDA-35, 1
  • SEDA-36, 1]
  • Studies
  • Cases
  • Ecstasy (3,4-Methylenedioxy-N-Methylamphetamine
  • MDMA)
  • Studies
  • Cases
  • Methylphenidate [SEDA-15, 2307
  • SEDA-32, 10
  • SEDA-33, 7
  • SEDA-34, 5
  • SEDA-35, 1
  • SEDA-36, 1]
  • Studies
  • Cases
  • Methylxanthines
  • Caffeine [SEDA-15, 588
  • SEDA-32, 14
  • SEDA-33, 11
  • SEDA-34, 6
  • SEDA-36, 1]
  • Studies
  • Cases
  • Selective Norepinephrine Reuptake Inhibitors Atomoxetine [SEDA-33, 6
  • SEDA-34, 4
  • SEDA-36, 1]
  • Studies
  • Cases
  • Vigilance Promoting Drugs
  • Modafinil and Armodafinil [SEDA-15, 2369
  • SEDA-32, 6
  • SEDA-33, 11
  • SEDA-34, 6
  • SEDA-36, 1]
  • Studies
  • Cases
  • Drugs That Suppress Appetite [SEDA-30, 7
  • SEDA-32, 16
  • SEDA-33, 13
  • SEDA-34, 8
  • SEDA-36, 1]
  • Lorcaserin
  • Studies
  • Naltrexone Sustained-Release/Bupropion Sustained-Release
  • Studies
  • Phentermine [SEDA-15, 2804
  • SEDA-32, 17
  • SEDA-33, 13
  • SEDA-34, 8
  • SEDA-36, 1]
  • Cases
  • Phentermine/Topiramate Extended Release
  • Studies
  • Parasympathomimetics [SEDA-32, 19
  • SEDA-33, 15
  • SEDA-34, 9]
  • Rivastigmine [SEDA-15, 3072
  • SEDA-32, 20
  • SEDA-33, 16
  • SEDA-34, 10
  • SEDA-36, 1]
  • Studies
  • Cases
  • Donepezil [SEDA-15, 1179
  • SEDA-32, 19
  • SEDA-33, 15
  • SEDA-34, 10
  • SEDA-36, 1]
  • Studies
  • Cases
  • Galantamine [SEDA-36, 1]
  • Studies
  • Cases
  • References
  • Chapter 2: Antidepressants
  • General
  • Hematological
  • Perioperative Bleeding
  • Perioperative Bleeding and Hip Surgery
  • Combination with Anticoagulation Therapies
  • Gastrointestinal (GI) Bleeding
  • Brain Hemorrhage
  • Postpartum Hemorrhage
  • Reproductive System (Pregnancy, Development and Infancy)
  • Spontaneous Abortion/Miscarriage
  • Teratogenesis-General Findings
  • Teratogenesis-Cardiac Malformations
  • Teratogenesis-Neurological Abnormalities
  • Teratogenesis-Talipes Equinovarus ("Clubfoot")
  • Preterm Birth and Low Birth Weight
  • Apgar Scores
  • Persistent Pulmonary Hypertension of the Newborn
  • Respiratory Distress
  • Poor Neonatal Adaptation (PNA)
  • Infant Neurodevelopment/Development
  • Autism
  • Attention Deficit Hyperactivity Disorder
  • Cardiovascular
  • Coronary Heart Disease (CHD)
  • Mortality Rates/Cardiac Arrest
  • Idiopathic Pulmonary Arterial Hypertension
  • Takotsubo Cardiomyopathy (TTC)
  • Sensory Systems
  • Eye-Cataract
  • Metabolism
  • Weight Gain
  • Musculoskeletal
  • Fracture/Bone Loss
  • Psychiatric
  • Suicide Risk
  • Gastrointestinal
  • Microscopic Colitis (MC)
  • Selective Serotonin Re-Uptake Inhibitors (SSRIs) [SED-15, 3109
  • SEDA-31, 18
  • SEDA-32, 33
  • SEDA-33, 26
  • SEDA-34, 17
  • SEDA-35...
  • Citalopram and Escitalopram
  • Cardiovascular
  • QTc Interval and Torsade de Pointes
  • Fluoxetine
  • Dermatological
  • Angioedema
  • Chronic Angle-Closure Glaucoma
  • Acute Generalized Exanthematous Pustulosis (AGEP)
  • Sertraline
  • Ophthalmic
  • Acute Angle-Closure Glaucoma
  • Dermatological
  • Acneiform Eruption
  • Serotonin and Noradrenaline Re-Uptake Inhibitors (SNRIs)
  • Venlafaxine and Desvenlafaxine [SED-15, 3614
  • SEDA-31, 22
  • SEDA-32, 35
  • SEDA-33, 32
  • SEDA-34, 20
  • SEDA-35, 32
  • SEDA-36, 19]
  • Venlafaxine
  • Peripheral Edema
  • Seizures in a Neonate
  • Duloxetine
  • Acute Angle-Closure Glaucoma
  • Spontaneous Abortion
  • Neurological
  • Paresthesias
  • Galactorrhoea and Restless Legs Syndrome
  • Milnacipran
  • Tolerability
  • Levomilnacipran
  • Other Antidepressants
  • Agomelatine
  • Hepatotoxicity
  • Gynecomastia
  • Bupropion (Amfebutamone) [SED-15, 108
  • SEDA-31, 22
  • SEDA-32, 35
  • SEDA-33, 33
  • SEDA 34, 21
  • SEDA-35, 34
  • SEDA-36, 21]
  • Neurological
  • Stuttering
  • Hyponatremia
  • Renal Impairment
  • Hematologic
  • Drug Abuse
  • Seizures
  • Mirtazapine [SED-15, 2536
  • SEDA-32, 36
  • SEDA-33, 33
  • SEDA-34, 22
  • SEDA-35, 34
  • SEDA-36, 21]
  • Peripheral Edema
  • Sleep-Related Movement Disorder
  • Vortioxetine
  • References
  • Chapter 3: Lithium
  • Introduction
  • Organs and Systems
  • Nervous System
  • Psychiatric
  • Delirium
  • Mild Cognitive Impairment
  • Endocrine
  • Thyroid
  • Parathyroid
  • Renal/Urinary Tract
  • Nephrotoxicity
  • Nephrogenic Diabetes Insipidus
  • Biomarkers of Kidney Injury
  • Skin
  • Acne
  • Respiratory
  • Acute Respiratory Distress Syndrome
  • Metabolism
  • Weight Gain
  • Electrolyte Balance
  • Second-Generation Effects
  • Susceptibility Factors
  • Gender
  • Elderly
  • Renal Transplant
  • Interactions
  • Antidepressants and Antipsychotics
  • Muscle Blockers and Anesthesia
  • Non-Steroidal Anti-Inflammatory Drugs
  • Diagnosis of Adverse Drug Reactions
  • Renal Imaging
  • Management of Adverse Drug Reactions
  • Pharmacogenomics
  • References
  • Chapter 4: Drugs of Abuse
  • Introduction
  • Cannabinoid
  • Nervous Systems
  • Psychiatric
  • Cardiovascular Disease
  • Urinary Tract
  • Alcohol
  • Liver
  • Tumorigenecity
  • Second Generation Effects
  • Benzodiazepines
  • Sympathomimetics-Cocaine
  • Sympathomimetics-Pediatric Exposure
  • Opioids-Heroin
  • Urinary Tract
  • Electronic Cigarettes (E-Cigarettes)
  • Conclusion
  • References
  • Chapter 5: Hypnosedatives and Anxiolytics
  • Benzodiazepines
  • Alprazolam
  • Psychological
  • Psychiatric
  • Central Nervous System
  • Benzodiazepines
  • Psychological
  • Clobazam
  • Drug-Drug Interaction
  • Diazepam
  • Central Nervous System
  • Flubromazepam
  • Pharmacokinetics
  • Lorazepam
  • Ophthalmologic
  • Midazolam
  • Drug-Drug Interaction
  • Drug-Drug Interaction
  • Hypnosedatives and Benzodiazepine-Like Drugs
  • Buspirone
  • Drug Formulation
  • Chloral Hydrate
  • Paediatrics
  • Paediatric
  • Eszopiclone
  • Central Nervous System
  • Melatonin
  • Drug-Drug Interaction
  • Sodium Oxybate
  • Psychological
  • Psychiatric
  • Zolpidem
  • Psychological
  • Driving
  • Head Injury
  • Zopiclone
  • Psychological
  • References
  • Chapter 6: Antipsychotic Drugs
  • General [SEDA-15, 2438
  • SEDA-32, 83
  • SEDA-33, 89
  • SEDA-34, 51
  • SEDA-35, 85
  • SEDA-36, 59]
  • Comparative Studies
  • Observational Studies
  • Systematic Reviews
  • Cardiovascular
  • Nervous System
  • Endocrine
  • Metabolism
  • Gastrointestinal
  • Hematologic
  • Susceptibility Factors
  • Toxicity
  • Susceptibility Factors
  • Drug-Drug Interactions
  • Obsessive Compulsive Symptoms
  • Individual Drugs
  • Amisulpride [SEDA-32, 92
  • SEDA-33, 99
  • SEDA-34, 60
  • SEDA-35, 85
  • SEDA-36, 59]
  • Observational Studies
  • Controlled Studies
  • Nervous System
  • Metabolic
  • Aripiprazole [SEDA-32, 93
  • SEDA-33, 99
  • SEDA-34, 60
  • SEDA-35, 96
  • SEDA-36, 59]
  • Controlled Studies
  • Systematic Reviews
  • Reviews
  • Observational Studies
  • Nervous System
  • Psychiatric
  • Metabolism
  • Endocrine
  • Psychiatric
  • Gastro-Intestinal
  • Drug-Drug Interactions
  • Asenapine [SEDA-37, 69]
  • Observational Studies
  • Metabolism
  • Skin
  • Blonanserin
  • Systematic Reviews
  • Nervous System
  • Chlorpromazine [SEDA-35, 85
  • SEDA-36, 59]
  • Observational Studies
  • Systematic Reviews
  • Clozapine [SEDA-32, 94
  • SEDA-33, 102
  • SEDA-34, 6
  • SEDA-35, 99
  • SEDA-36, 59]
  • Observational Studies
  • Systematic Reviews
  • Reviews
  • Cardiovascular
  • Nervous System
  • Psychiatric
  • Metabolism
  • Hematologic
  • Salivary Glands
  • Gastrointestinal
  • Musculoskeletal
  • Sexual
  • Body Temperature
  • Susceptibility Factors
  • Drug Overdose
  • Cyamemazine
  • Gastrointestinal
  • Droperidol [SEDA-36, 59]
  • Cardiovascular
  • Nervous System
  • Flupenthixol
  • Observational Studies
  • Systematic Reviews
  • Fluphenazine
  • Systematic Reviews
  • Haloperidol [SEDA-35, 107
  • SEDA-36, 59]
  • Sytematic Reviews
  • Nervous System
  • Iloperidone [SEDA-33, 103
  • SEDA-35, 109
  • SEDA-36, 59]
  • Reviews
  • Sexual Function
  • Levomepromazine (Methotrimeprazine) [SEDA-36, 59]
  • Observational Studies
  • Levosulpiride
  • Cardiovascular
  • Loxapine [SEDA-35,108
  • SEDA-36, 59]
  • Controlled Studies
  • Lurasidone
  • Controlled Studies
  • Observational Studies
  • Reviews
  • Olanzapine [SEDA-32, 99
  • SEDA-33, 104
  • SEDA-34, 66
  • SEDA-35, 108
  • SEDA-36, 59]
  • Controlled Studies
  • Observational Studies
  • Systematic Reviews
  • Reviews
  • Nervous System
  • Psychiatric
  • Metabolism
  • Fluid Balance
  • Gastrointestinal
  • Susceptibility Factors
  • Toxicity
  • Paliperidone [SED-33, 108, SEDA-35, 85
  • SEDA-36, 59]
  • Controlled Studies
  • Observational Studies
  • Cardiovascular
  • Nervous System
  • Metabolic
  • Gastrointestinal
  • Perazine [SEDA-36, 59]
  • Systematic Reviews
  • Pericyazine
  • Systematic Reviews
  • Perospirone [SEDA-36, 59]
  • Systematic Reviews
  • Nervous System
  • Perphenazine [SEDA-32, 104
  • SEDA-35, 85
  • SEDA-36, 59]
  • Observational Studies
  • Systematic Reviews
  • Prochlorperazine [SEDA-35, 85
  • SEDA-36, 59]
  • Susceptibility Factors
  • Quetiapine [SEDA-32, 104
  • SEDA-33, 110
  • SEDA-34, 69
  • SEDA-35, 85
  • SEDA-36, 59]
  • Observational Studies
  • Systematic Reviews
  • Nervous System
  • Gastrointestinal
  • Risperidone [SEDA-32, 107
  • SEDA-33, 111
  • SEDA-34, 70
  • SEDA-35, 85
  • SEDA-36, 59]
  • Cardiovascular
  • Nervous System
  • Endocrine
  • Susceptibility Factors
  • Sertindole [SEDA-32, 110
  • SEDA-33, 114
  • SEDA-34, 73
  • SEDA-35, 85
  • SEDA-36,59]
  • Reviews
  • Sulpiride [SEDA-35,115
  • SEDA-36]
  • Observational Studies
  • Ziprasidone [SEDA-32, 111
  • SEDA-33, 114
  • SEDA-34, 74
  • SEDA-35, 85
  • SEDA-36, 59]
  • Controlled Studies
  • Observational Studies
  • Cardiovascular
  • Nervous System
  • Metabolism
  • Allergic
  • Zotepine [SEDA-33, 114
  • SEDA-35,116
  • SEDA-36, 59]
  • Observational Studies
  • References
  • Chapter 7: Antiepileptics
  • Brivaracetam
  • Introduction
  • Placebo-Controlled Trials
  • Pharmacogenomics
  • Drug-Drug Interactions
  • Carbamazepine [SEDA-31, 107
  • SEDA-32, 126
  • SEDA-33, 132
  • SEDA-34, 94
  • SEDA-35, 135
  • SEDA-36, 88]
  • Meta-Analysis
  • Cardiovascular
  • Nutrition
  • Skin
  • Drug Overdose
  • Sexual and Reproductive Function
  • Pharmacogenomics
  • Eslicarbazepine [SEDA-34, 97
  • SEDA-35, 136
  • SEDA-36, 89]
  • Placebo-Controlled Trials
  • Observational
  • Skin
  • Ethosuximide [SEDA-36, 90]
  • Neurologic
  • Felbamate [SEDA 33, 136
  • SEDA-34, 198
  • SEDA-35, 137
  • SEDA-36, 90]
  • Observational
  • Systematic Review
  • Gabapentin [SEDA-31, 110
  • SEDA-32, 131
  • SEDA-33, 136
  • SEDA-34, 99
  • SEDA-35, 137
  • SEDA-36, 90]
  • Nervous System
  • Endocrine
  • Urinary Tract
  • Drug Monitoring
  • Lacosamide [SEDA-33, 139
  • SEDA-34, 101
  • SEDA-35, 138
  • SEDA-36, 90]
  • Systematic Review
  • Observational
  • Cardiac
  • Neurologic
  • Psychiatric
  • Pharmacokinetics
  • Drug-Drug Interactions
  • Lamotrigine [SEDA-31, 113, SEDA-32, 134, SEDA-33, 141
  • SEDA-34, 101
  • SEDA-35, 138
  • SEDA-36, 91]
  • Comparative Studies
  • Nervous System
  • Psychiatric
  • Skin
  • Pharmacogenomics
  • Death
  • Levetiracetam [SEDA-31, 116
  • SEDA-32, 137
  • SEDA-33, 146
  • SEDA-34, 104
  • SEDA-35, 140
  • SEDA-36, 91]
  • Observational
  • Nervous System
  • Psychiatric
  • Skin
  • Renal
  • Liver
  • Hair
  • Drug Overdose
  • Teratogenicity
  • Drug-Drug Interaction
  • Oxcarbazepine [SEDA-31, 118
  • SEDA-32, 141
  • SEDA-33, 151
  • SEDA-34, 106
  • SEDA-35, 141
  • SEDA-36, 93]
  • Cardiovascular
  • Nervous System
  • Musculoskeletal
  • Electrolyte Balance
  • Pharmacogenomics
  • Perampanel [SEDA-35, 142
  • SEDA-36, 93]
  • Systematic Review
  • Psychiatric
  • Liver
  • Drug Overdose
  • Phenobarbital, Primidone, and Other Barbiturates [SEDA-32, 145
  • SEDA-33, 154
  • SEDA-34, 107
  • SEDA-35, 142
  • SEDA-36, 93]
  • Cardiovascular
  • Skin
  • Immunologic
  • Pharmacogenomics
  • Therapeutic Drug Monitoring
  • Phenytoin and Fosphenytoin [SEDA-31, 120
  • SEDA-32, 145
  • SEDA-33, 155
  • SEDA-34, 108
  • SEDA-35, 143
  • SEDA-36, 94]
  • Neurologic
  • Endocrine
  • Mouth and Teeth
  • Skin
  • Drug Overdose
  • Drug Administration Route
  • Pharmacogenomics
  • Drug-Drug Interactions
  • Pregabalin [SEDA-32, 146
  • SEDA-33, 157
  • SEDA-34, 110
  • SEDA-35, 145
  • SEDA-36, 95]
  • Nervous System
  • Psychiatric
  • Sexual Function
  • Retigabine/Ezogabine [SEDA-34, 112
  • SEDA-35, 146
  • SEDA-36, 96]
  • Skin
  • Drug Dosage Regimens
  • Drug-Drug Interactions
  • Pharmacokinetics
  • Rufinamide [SEDA-33, 160
  • SEDA-34, 113
  • SEDA-35, 146
  • SEDA-36, 96]
  • Placebo-Controlled Trials
  • Systematic Review
  • Observational Studies
  • Hematologic
  • Skin
  • Topiramate [SEDA-31, 124
  • SEDA-32, 148
  • SEDA-33, 161
  • SEDA-34, 114
  • SEDA-35, 147
  • SEDA-36, 96]
  • Psychiatric
  • Sensory Systems
  • Urinary Tract
  • Skin
  • Pediatrics
  • Drug-Drug Interactions
  • Pharmacokinetics
  • Body Temperature
  • Valproic Acid [SEDA-31, 126
  • SEDA-32, 153
  • SEDA-33, 167
  • SEDA-34, 116
  • SEDA-35, 149
  • SEDA-36, 97]
  • Liver
  • Immunologic
  • Neurologic
  • Hematologic
  • Pancrease
  • Multi-organ Failure
  • Teratogenicity
  • Drug Overdose
  • Vigabatrin [SEDA-31, 136
  • SEDA-32, 160
  • SEDA-33, 176
  • SEDA-34, 121
  • SEDA-35, 154
  • SEDA-36, 99]
  • Neurologic
  • Sensory System
  • Zonisamide [SEDA-31, 137
  • SEDA-32, 161
  • SEDA-33, 179
  • SEDA-34, 123
  • SEDA-35, 154
  • SEDA-36, 100]
  • Meta-Analysis
  • Observational
  • Psychiatric
  • Urinary Tract
  • Lactation
  • References
  • Chapter 8: Opioid Analgesics and Narcotic Antagonists
  • Low-Dose Ketamine as an Analgesia Adjunct
  • Opioid Receptor Agonists
  • General Opioid Receptor Agonists
  • Alfentanil [SED-15, 72
  • SEDA-34, 152
  • SEDA-35, 173
  • SEDA-36, 108]
  • Neurological
  • Codeine [SED-15, 880
  • SEDA-34, 152
  • SEDA-35, 174
  • SEDA-36, 108]
  • Pharmacogenetics
  • Respiratory
  • Long-Term Effects
  • Drug Abuse
  • Dextrometrophan [SED-15, 1088
  • SEDA-34, 153
  • SEDA-35, 174
  • SEDA-36, 108]
  • Psychiatric
  • Diamorphine [SED-15, 1096
  • SEDA-34, 153
  • SEDA-35, 175
  • SEDA-36, 108]
  • Ear, Nose, Throat
  • Nervous System
  • Death
  • Long-Term Effects
  • Drug Withdrawal
  • Susceptibility Factors
  • Genetic Factors
  • Dihydrocodeine [SED-15, 1125
  • SEDA-34, 154
  • SEDA-35, 175
  • SEDA-36, 108]
  • Fentanyl [SED-15, 1346
  • SEDA-34, 154
  • SEDA-35, 176
  • SEDA-36, 109]
  • Psychiatric
  • Nervous System
  • Abuse
  • Musculoskeletal
  • Cardiovascular
  • Hydrocodone [SED-15, 1702
  • SEDA-34, 156
  • SEDA-35, 177
  • SEDA-36, 109]
  • Cardiovascular
  • Death
  • Susceptibility Factors
  • Genetic Factors
  • Methadone [SED-15, 2270
  • SEDA-34, 157
  • SEDA-35, 177
  • SEDA-36, 110]
  • Nervous System
  • Skin
  • Gastrointestinal
  • Cardiac
  • Morphine [SED-15, 2386
  • SEDA-34, 159
  • SEDA-35, 181
  • SEDA-36, 111]
  • Susceptibility Factors
  • Metabolism
  • Oxycodone [SED-15, 2651
  • SEDA-34, 161
  • SEDA-35, 182
  • SEDA-36, 111]
  • ENT
  • Neuro
  • Susceptibility Factors
  • Interactions
  • Drug-Drug Interactions
  • Long-Term Effects
  • Drug Abuse
  • Papaverine [SED-15, 2678
  • SEDA-34, 162
  • SEDA-35, 183
  • SEDA-36, 112]
  • Cardiac
  • Pethidine (Meperidine) [SED-15, 2791
  • SEDA-34, 163
  • SEDA-35, 183
  • SEDA-36, 112]
  • Remifentanyl [SED-15, 3030
  • SEDA-34, 163
  • SEDA-35, 184
  • SEDA-36, 112]
  • Gastrointestinal
  • Neurological
  • Tramadol [SED-15, 3469
  • SEDA-34, 165
  • SEDA-35, 184
  • SEDA-36, 112]
  • Psychiatric
  • Partial Opioid Receptor Agonists
  • Buprenorphine [SED-15, 571
  • SEDA-34, 166
  • SEDA-35, 185
  • SEDA-36, 113]
  • Drug Administration
  • Overdose
  • Allergic Reaction
  • Opioid Receptor Antagonists
  • Methylnaltrexone [SED-15, 2307
  • SEDA-34, 168
  • SEDA-35, 186
  • SEDA-36, 114]
  • Nervous System
  • Gastrointestinal
  • Naloxone [SED-15, 2421
  • SEDA-35, 186
  • SEDA-36, 114]
  • Drug-Drug Interaction
  • Neurologic
  • Naltrexone [SED-15, 2423
  • SEDA-34, 168
  • SEDA-35, 186
  • SEDA-36, 114]
  • Psychiatric
  • References
  • Chapter 9: Anti-Inflammatory and Antipyretic Analgesics and Drugs Used in Gout
  • Amidopyrine and Related Compounds [SEDA-34, 184
  • SEDA-35, 197]
  • Metamizole (Dipyrone, Normalidopyrine, Noraminosulfone) [SED-15, 226
  • SEDA-34, 184
  • SEDA-35, 197]
  • Hematologic
  • Renal
  • Drug-Drug Interaction
  • Aniline Derivatives [SED-15, 2679
  • SEDA-34, 184
  • SEDA-35, 197]
  • Paracetamol (Acetaminophen) [SED-15, 2679
  • SEDA-34, 185
  • SEDA 35, 197]
  • Cardiovascular
  • Respiratory
  • Metabolism
  • Gastrointestinal
  • Liver
  • Skin
  • Teratogenicity
  • Arylalkanoic Acid Derivatives [SED-15, 2555
  • SEDA-34, 185
  • SEDA-35, 200
  • SEDA-36, 119-120]
  • Diclofenac [SEDA-34, 185
  • SEDA-35, 200
  • SEDA-36, 119]
  • Cardiovascular
  • Skin
  • Pregnancy
  • Ibuprofen [SEDA-34, 185
  • SEDA-35, 200
  • SEDA-36, 119]
  • Renal
  • Oral
  • Gastrointestinal
  • Dependence
  • Pregnancy
  • Ketorolac [SEDA-34, 186
  • SEDA-35, 200]
  • Cardiovascular
  • Otolaryngological
  • Pulmonary
  • Loxoprofen
  • Endocrine
  • Special Review - Controversial use of Ketorolac
  • Otolaryngological
  • Cardiovascular
  • Prolonged Bleeding Time
  • Postoperative Bleeding
  • Increased Use of Additional Hemostatic Measures
  • COX-2 Selective Inhibitors [SEDA-34, 186
  • SEDA-35, 201
  • SEDA 36, 120]
  • Celecoxib [SEDA-34, 186
  • SEDA-35, 201
  • SEDA-36, 124]
  • Cardiovascular
  • Gastrointestinal
  • Etoricoxib [SEDA-34, 187
  • SEDA-35, 201
  • SEDA-36, 126]
  • Immunologic
  • Rofecoxib [SEDA-34, 187
  • SEDA-35, 201
  • SEDA-36, 126]
  • Cardiovascular
  • Valdecoxib
  • Hematological
  • Indoleacetic Acids [SEDA-34, 187]
  • Indomethacin [SEDA-34, 187]
  • Nervous System
  • Teratogenicity
  • Drug Formulations
  • Oxicams [SEDA-34, 187
  • SEDA-35, 201
  • SEDA-36, 126]
  • Piroxicam [SEDA-36, 127]
  • Pregnancy
  • Skin
  • Propionic Acid Derivatives [SEDA-36, 127]
  • Naproxen [SEDA-35, 200
  • SEDA-36, 127]
  • Pregnancy
  • Comparative Study
  • Systematic Reviews
  • Hematologic
  • Immunologic
  • Drug-Drug Interactions
  • Salicylates [SED-15, 15
  • SEDA-34, 188
  • SEDA-35, 202
  • SEDA-36, 127]
  • Acetylsalicylic Acid (Aspirin) [SED-15, 15
  • SEDA-34, 188
  • SEDA-35, 202
  • SEDA-36, 127]
  • Sensory Systems
  • Genetic Factors
  • Drug-Drug Interaction
  • Sensory Systems
  • Salsalate
  • Cardiovascular
  • Metabolism
  • Miscellaneous Drugs
  • Nefopam [SED-15, 2433
  • SEDA-34, 188
  • SEDA-35, 207
  • SEDA-36, 128]
  • Drug Dosage Regimens
  • Nimesulide [SED-15, 2524
  • SEDA-33, 249
  • SEDA-36, 128]
  • Sensory Systems
  • Drugs Used in the Treatment of Gout
  • Allopurinol [SED-15, 80
  • SEDA-34, 189
  • SEDA-35, 207
  • SEDA-36, 129]
  • Skin
  • Genetic
  • Hematologic Malignancy
  • Renal Disease
  • Colchicine [SEDA-34, 189
  • SEDA-35, 208]
  • Neuromuscular Function
  • Drug-Drug Interaction
  • Febuxostat [SEDA-34, 250
  • SEDA-35, 209
  • SEDA-36, 129]
  • Incidence
  • Nephrology
  • Neurology
  • Leflunomide [SEDA-36, 131]
  • Pharmacogenomics
  • Gastrointestinal
  • Risk Factors for Infection
  • Skin
  • References
  • Chapter 10: General Anaesthetics and Therapeutic Gases
  • Introduction
  • Etomidate
  • Trauma
  • Sepsis
  • Cardiovascular
  • Ketamine
  • Nervous System
  • Psychological
  • Psychiatric-1
  • Psychiatric-2
  • Liver
  • Urinary Tract
  • Death
  • Thiopentone
  • Nervous System
  • Gastrointestinal
  • Methoxetamine
  • Psychological
  • Propofol
  • Uses
  • Sedation
  • Cardiovascular
  • Respiratory
  • Neurological
  • Pain
  • Psychiatric
  • Liver
  • Urinary Tract
  • Endocrine
  • Skin
  • Immunological
  • Death
  • Fospropofol
  • Dexmedetomidine
  • Sedation
  • Cardiovascular
  • Desflurane
  • Nervous System
  • Ear, Nose and Throat
  • Immunologic
  • Other
  • Isoflurane
  • Nervous System
  • Methoxyflurane
  • Psychological
  • Nitrous Oxide
  • Nervous System
  • Gastrointestinal
  • Immunological
  • Psychological
  • Sevoflurane
  • Sensory Systems
  • Other
  • Psychological
  • Nervous System
  • Immunologic
  • Respiratory
  • Cardiovascular
  • Neuromuscular Function
  • Delayed Onset of Malignant Hyperthermia
  • Liver
  • References
  • Chapter 11: Local Anesthetics
  • General Information
  • Combined Anesthetics
  • Cardiovascular
  • Benign Supraventricular Arrhythmias: Bupivacaine vs. Ropivacaine
  • Cell Toxicity
  • Nervous System
  • Delayed Manifestation of Local Anesthetic Local Toxicity After Combined Psoas Compartment and Sciatic Nerve Block
  • Toxicity After Spinal Anesthesia
  • Benzocaine
  • Dermatologic
  • Acute Generalized Exanthematous Pustulosis After Benzocaine Spray
  • Hematologic
  • Methemoglobinemia After Benzocaine Administration
  • Methemoglobinemia After Ingesting a Benzocaine Lollipop
  • Methemoglobinemia After Using Benzocaine Spray for Pain on Urination
  • Bupivacaine
  • Anatomic
  • Bupivacaine Crystal Formation After Prolonged Epidural Infusion
  • Cardiovascular
  • Efficacy of Resuscitation with Intralipid
  • Lipid Resuscitation in a Pediatric Patient
  • Ventricular Tachycardia After a Penile Block
  • Nervous System
  • Severe Flaccid Paralysis After Spinal Anesthesia
  • Toxicity in a Parturient After a Transverse Abdominis Plane Block
  • EMLA
  • Nervous System
  • Seizures and Oxygen-Resistant Cyanosis After Application of EMLA Cream
  • Levobupivacaine
  • Cardiovascular
  • Technique of Block Makes a Difference
  • Efficacy of Resuscitation with Intralipid
  • Nervous System
  • Seizures After Transversus Abdominis Plane Blocks
  • Lidocaine
  • Cardiovascular
  • Cardiac Arrest After Ingestion of Viscous Lidocaine
  • Compounded Ointment and Toxicity in a Pediatric Patient
  • Lidocaine Toxicity During Cardiac Intervention
  • Cell Toxicity
  • Dermatologic
  • Lidocaine Contact Allergy is Becoming More Prevalent
  • Infectious
  • Spinal Epidural Abscess After Continuous Epidural Block
  • Nervous System
  • Superficial Skin Necrosis and Neurological Complications Following Lidocaine Administration for Dental Procedure
  • Neurologic Toxicity of Lidocaine During Awake Intubation in a Patient with a Tongue Base Abscess
  • Prolonged Local Anesthetic Duration of Action in Patients on Chronic Lithium Therapy
  • Oxybuprocaine
  • Dermatologic
  • Toxic Epitheliopathy in a Patient with Sjogren's Syndrome
  • Ropivacaine
  • Cardiovascular
  • Toxic Dose of Ropivacaine After a Paravertebral Block in a Patient with Severe Hypoalbuminemia
  • Miscommunication Leads to a Local Anesthetic Overdose
  • LAST After Local Infiltration Analgesia Following a Polyethylene Tibial Insert Exchange
  • Nervous System
  • Delayed Arousal After an Inadvertent Intravascular Epidural Catheter Placement
  • References
  • Chapter 12: Neuromuscular Blocking Agents and Skeletal Muscle Relaxants
  • Depolarizing Neuromuscular Blocking Agents
  • Succinylcholine (Suxamethonium) (SEDA-28, 155
  • SEDA-31, 247
  • SEDA-32, 273
  • SEDA-33, 299
  • SEDA-34, 221
  • SEDA-35, 173, SEDA-36)
  • Organs and Systems
  • Cardiovascular
  • Musculoskeletal
  • Immunologic
  • Hypersensitivity Reactions
  • Anaphylaxis
  • Susceptibility Factors
  • Genetic Factors
  • Non-Depolarizing Neuromuscular Blockers
  • Organs and Systems
  • Cardiovascular
  • Neuromuscular Blockers: Reversal Agents
  • Calabadion 1
  • Sugammadex
  • General Information
  • Immunologic
  • Hypersensitivity Reactions
  • Interactions
  • Drug-Drug Interactions
  • Skeletal Muscle Relaxants
  • General Information
  • Baclofen (SEDA-35, 173
  • SEDA-36)
  • General Information
  • Organs and Systems
  • Cardiovascular
  • Central Nervous System and Urinary Tract
  • Sensory System: Ear
  • Psychological
  • Drug Administration
  • Drug Interaction(s)
  • Botulinum Toxin (SEDA-35, 174
  • SEDA-36)
  • General Information
  • Organs and Systems
  • Neuromuscular Function
  • Immunologic
  • Hypersensitivity Reactions
  • Carisoprodol
  • Susceptibility Factors
  • Age and Sex
  • References
  • Chapter 13: Drugs that Affect Autonomic Functions or the Extrapyramidal System
  • Drugs that Stimulate Both Alpha- and Beta-Adrenoceptors [SEDA-33, 313
  • SEDA-34, 233
  • SEDA-35, 255
  • SEDA-36, 179]
  • Adrenaline (Adrenaline) and Noradrenaline (Noradrenaline) [SEDA-32, 281
  • SEDA-33, 259
  • SEDA-34, 233
  • SEDA-35, 255
  • SEDA-36,...
  • Reproductive System
  • Randomized Clinical Trial
  • Ephedrine [SEDA-32, 282
  • SEDA-33, 317
  • SEDA-34, 235
  • SEDA-35, 256
  • SEDA-37, 000]
  • Systematic Review
  • Randomized Controlled Trial
  • Drugs that Predominantly Stimulate Alpha 1-Adrenoceptors [SEDA-33, 318
  • SEDA-34, 236
  • SEDA-35, 257
  • SEDA-36, 186]
  • Systematic Review
  • Drugs that Stimulate ß1-Adrenoceptors [SEDA-33, 265
  • SEDA-34, 285
  • SEDA-35, 257
  • SEDA-36, 187]
  • Dobutamine [SEDA-33, 319
  • SEDA-34, 285
  • SEDA-35, 257
  • SEDA-36, 187]
  • Adverse Effects During Dobutamine Stress Echocardiography
  • Cardiovascular
  • Hematologic
  • Management of Adverse Drug Reactions
  • Drugs that Stimulate ß2-Adrenoceptors
  • Indacaterol [SEDA-33, 361-2
  • SEDA-34, 318
  • SEDA-36, 188]
  • Randomized Controlled Trial
  • Randomized Controlled Trial
  • A Comparative study of salmeterol vs formoterol
  • Systematic Review
  • Salbutamol [SEDA-21, 182
  • SEDA-22, 190
  • SEDA-35, 318
  • SEDA-36, 189]
  • Systematic Review
  • Randomized Controlled Trial
  • Randomized Controlled Trial
  • Background
  • Drugs that Stimulate Dopamine Receptors [SEDA-33, 266
  • SEDA-34, 283
  • SEDA-35, 262
  • SEDA-36, 190]
  • Systematic Review
  • Pharmacogenetics
  • Cabergoline [SEDA-17, 169
  • SEDA-35, 262
  • SEDA-36, 190]
  • Systemic Review
  • Hematological
  • Rotigotine [SEDA-35, 264]
  • Systematic Review
  • Randomized Controlled Trial
  • Nervous System
  • Open-Label Study
  • Apomorphine
  • Nervous System
  • Psychiatric
  • Gastrointestinal
  • Apomorphine vs Levodopa
  • Dopamine Receptor Agonists [SEDA-34, 242
  • SEDA-35, 261
  • SEDA-36, 191]
  • Placebo-Controlled Study
  • Review
  • Psychiatric
  • Piribedil [SEDA-35, 263]
  • Randomized Controlled Study
  • Psychiatric
  • Levodopa [SEDA-32, 285
  • SEDA-33, 320
  • SEDA-34, 286-8
  • SEDA-35, 259
  • SEDA-36, 192]
  • Systematic Reviews
  • Review
  • Placebo-Controlled Studies
  • Review
  • Management of Adverse Reactions
  • Drug Administration Route
  • Drug-Device Interaction
  • Mechanism
  • Psychiatric
  • Drug Formulations
  • Drugs that Affect the Cholinergic System [SEDA-31, 272
  • SEDA-32, 290
  • SEDA-33, 324
  • SEDA-34, 290-1, 318
  • SEDA-35, 266
  • SEDA...
  • Anticholinergic Drugs [SEDA-31, 273
  • SEDA-32, 290
  • SEDA-33, 324
  • SEDA-34, 290-1,318
  • SEDA-35, 266
  • SEDA-36, 199]
  • Randomized Trial
  • Genetic Factors
  • Placebo-Controlled Study
  • References
  • Chapter 14: Dermatological Drugs, Topical Agents, and Cosmetics
  • Introduction
  • Acne
  • Combination: Retinaldehyde, Glycolic Acid and Efectiose
  • Combination: Dapsone Gel and Oral Isotretinoin
  • Antifungals
  • Antifungal Treatments: Literature Review
  • Hair Loss Treatment
  • Minoxidil
  • Pigmentation Disorders
  • Tranexamic Acid
  • Ozenoxacin
  • Imiquimod
  • Psoriasis
  • Methotrexate
  • Cyclosporin
  • Tofacitinib
  • Calcipotriol Plus Betamethasone Dipropionate Gel
  • Cutaneous Side Effects from Antiviral Medications
  • Entecavir
  • Telaprevir and Boceprevir
  • Antiretroviral Therapy: Ritonavir-Boosted Darunavir
  • Cutaneous Side Effects from Cancer Medications
  • Mechlorethamine
  • Vemurafenib
  • Vismodegib
  • Hydroactive Colloid Gel
  • Imiquimod
  • Cutaneous Side Effects from Neurological Medications
  • Levetiracetam
  • Lacosamide
  • Antidepressants
  • Individual Medications
  • Acyclovir and Hydrocortisone
  • Arsenic Sulfide
  • Alternative Medicine: Panax Notoginseng Saponins
  • Ciprofloxacin
  • Corticosteroids
  • Dipeptidyl Peptidase IV Inhibitors
  • Doxycycline
  • Dupilumab
  • Hydralazine
  • Infliximab
  • Isoniazid
  • Leflunomide
  • Levamisole
  • Lidocaine and Prilocaine (EMLA)
  • Voriconazole
  • References
  • Chapter 15: Antihistamines (H1 Receptor Antagonists)
  • General
  • Special Review on Pharmacogenetics
  • Other Antihistamines
  • Bilastine [SED-35
  • SEDA-36, 234]
  • Cetirizine [SEDA-34, 272
  • SEDA-35
  • SEDA-36, 235]
  • Chlorphenamine [SEDA-33, 345
  • SEDA-34, 272
  • SEDA-36, 235]
  • Diphenhydramine [SEDA-34, 272
  • SEDA-35
  • SEDA-36, 235]
  • Doxylamine [SEDA-32, 307
  • SEDA-34, 273
  • SEDA-36, 235]
  • Fexofenadine [SEDA-36, 236]
  • Hydroxyzine [SEDA-36, 236]
  • Levocetirizine
  • Olopatadine [SEDA-36, 237]
  • Oxatomide [SEDA-36, 237]
  • Promethazine [SEDA-36, 237]
  • References
  • Chapter 16: Drugs that Act on the Respiratory Tract
  • Inhaled Glucocorticoids [SEDA-32, 311
  • SEDA-33, 353
  • SEDA-34, 277
  • SEDA-35, 309
  • SEDA-36, 241]
  • Inhaled Corticosteroids and Risk of Pneumonia
  • Susceptibility Factors
  • Age
  • Effects on Growth
  • One Year
  • Two Years
  • Three Years
  • Psychiatric
  • Endocrine
  • Interactions
  • Drug-Drug Interactions
  • Long Acting Beta2-Adrenoceptor Agonists [SEDA-32, 314
  • SEDA-33, 357
  • SEDA-34, 280
  • SEDA 35, 315
  • SEDA-36, 245]
  • Combination Therapy
  • Formoterol
  • Formoterol Versus Salmeterol
  • Indacaterol
  • Vilanterol
  • Vilanterol Versus Umeclidinium
  • Anticholinergic Drugs [SEDA-32, 318
  • SEDA-33, 363
  • SEDA-34, 282
  • SEDA-35, 318
  • SEDA-36, 247]
  • Glycopyrronium Bromide Versus Indacaterol
  • Cardiovascular
  • Respiratory
  • Glycopyrronium Bromide Versus Tiotropium
  • Respiratory
  • Cardiovascular
  • Ipratropium Bromide
  • Nervous System
  • Tiotropium Versus Aclidinium Bromide
  • Tiotropium Versus Ipratropium Bromide
  • Umeclidinium Bromide
  • Cardiovascular
  • Respiratory
  • Leukotriene Modifiers [SEDA-32, 319
  • SEDA-33, 366
  • SEDA-34, 283
  • SEDA-35, 320
  • SEDA-36, 251]
  • Montelukast
  • Interactions
  • Drug Interactions
  • Phosphodiesterase Inhibitors [SEDA-32, 321
  • SEDA-33, 367
  • SEDA-34, 284
  • SEDA-35, 321
  • SEDA-36, 252]
  • Cilomilast
  • Respiratory
  • Gastro-Intestinal
  • Roflumilast
  • Gastro-Intestinal
  • Psychiatric
  • Cardiovascular
  • Omalizumab (Xolair)
  • Endocrine
  • References
  • Chapter 17: Positive Inotropic Drugs and Drugs Used in Dysrhythmias
  • Cardiac Glycosides [SED-15, 648
  • SEDA-34, 287
  • SEDA-35, 327
  • SEDA-36, 257]
  • Drug-Drug Interaction
  • Ciprofloxacin
  • Dronedarone
  • Special Review-Digoxin Use and Mortality in Atrial Fibrillation
  • Other Positive Inotropes
  • Milrinone [SED-15, 2346
  • SEDA-34, 290
  • SEDA-35, 329]
  • Electrolyte Balance
  • Death
  • Antidysrhythmic Drugs
  • Ajmaline [SED-15, 45
  • SEDA-34, 292
  • SEDA-35, 332
  • SEDA-36, 258]
  • Liver
  • Susceptibility Factor: Age
  • Amiodarone [SED-15, 148
  • SEDA-34, 292
  • SEDA-35, 332
  • SEDA-36, 259]
  • Respiratory
  • Psychiatric
  • Musculoskeletal
  • Immunologic
  • Dofetilide [SED-15, 1173
  • SEDA-35, 338]
  • Cardiovascular
  • Dronedarone [SEDA-34, 296
  • SEDA-35, 338
  • SEDA-36, 262]
  • Observational Studies
  • Cardiovascular
  • Sensory Systems
  • Hematologic
  • Urinary Tract
  • Susceptibility Factors: Age and Concurrent Illness
  • Mexiletine [SED-15, 1370
  • SEDA-34, 298
  • SEDA-35, 341]
  • Immunologic
  • Propafenone [SED-15, 2939
  • SEDA-34, 298
  • SEDA-35, 342
  • SEDA-36, 263]
  • Drug-Drug Interaction
  • Sotalol [SED-15, 3170]
  • Cardiovascular
  • Susceptibility Factors: Age and Renal Disease
  • References
  • Chapter 18: Beta-Adrenoceptor Antagonists and Antianginal Drugs
  • Beta-Adrenoceptor Antagonists [SED-15, 452
  • SEDA-32, 363
  • SEDA-33, 397
  • SEDA-34, 303
  • SEDA-35, 351
  • SEDA-36, 267]
  • Beta-Blockers
  • Pulmonary
  • Beta-Blockers Are Associated with a Lower Forced Expiratory Volume in 1second (FEV1) and Forced Vital Capacity FVC
  • Pulmonary
  • Selective Beta-Blockers Are Better Tolerated But Not Completely Risk-Free
  • Liver
  • Hepatorenal Syndrome
  • Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis Treated with Non-Selective ...
  • Second Generation Effects
  • Pregnancy
  • Pregnancy
  • Esmolol
  • Psychiatric
  • Levobunolol
  • Cardiovascular
  • Bradyarrhythmias Were Associated to Topical Solution of Levobunolol
  • Nebivolol
  • Cardiovascular
  • Extreme Bradycardia Has Been Associated with Nebivolol
  • Metabolism and Electrolyte Imbalance
  • Hypoglycemia, Polycythemia and Hyponatremia Have Been Associated to Nebivolol Use During Pregnancy
  • Propranolol
  • Dermatological
  • Susceptibility Factors
  • Age
  • Metabolism and Electrolyte Imbalance
  • Timolol
  • Central Nervous System
  • Interactions
  • Drug-Drug Interactions
  • Propranolol
  • Lack of Pharmacokinetic Interaction Between Topiramate and Propranol
  • Long-Term Effects
  • Drug Misuse
  • Medication Error Associate with the Use of Beta-Blockers
  • Potassium Channel Activators
  • Nicorandil [SED-15, 2505
  • SEDA-32, 365
  • SEDA-33, 400
  • SEDA-34, 305
  • SEDA-35, 353
  • SEDA-36, 270]
  • Hematologic
  • Sensory System
  • Calcium Channel Blockers [SED-15, 598
  • SEDA-32, 366
  • SEDA-33, 401
  • SEDA-34, 306
  • SEDA-35, 354
  • SEDA-36, 270]
  • Cardiovascular
  • Flushing, Peripheral Edema, Headache
  • Breasts
  • Breast Cancer
  • Mouth and Teeth
  • Gingival Overgrowth
  • Amlodipine [SED-15, 175
  • SEDA-32, 367
  • SEDA-33, 401
  • SEDA-34, 307
  • SEDA-35, 354
  • SEDA-36, 270]
  • Cardiovascular
  • Purpura
  • Hypertension
  • Drug Administration
  • Drug Overdose
  • Nicardipine [SED-15, 2502
  • SEDA-32, 367
  • SEDA-33, 402
  • SEDA-34, 308
  • SEDA-35, 355
  • SEDA-36, 271]
  • Respiratory
  • Pulmonary Edema
  • Nifedipine [SED-15, 2516
  • SEDA-33, 402
  • SEDA-34, 308
  • SEDA-35, 355
  • SEDA-36, 271]
  • Cardiovascular
  • Intestinal Obstruction
  • Severe Hypotension
  • Respiratory
  • Pulmonary Edema
  • Verapamil [SED-15, 3618
  • SEDA-32, 367
  • SEDA-33, 403
  • SEDA-34, 308
  • SEDA-35, 356
  • SEDA-36, 272]
  • Drug Administration
  • Drug Overdose
  • A Case of Hypocalcemia Following Overdose of Verapamil and a Review Published
  • Non-Cardiogenic Pulmonary Edema and Life-Threatening Shock
  • Periportal Edema
  • References
  • Chapter 19: Drugs Acting on the Cerebral and Peripheral Circulations
  • Drugs Used in the Treatment of Arterial Disorders of the Brain and Limbs and in the Treatment of Migraine
  • Ergotamine [SEDA-36, 276] and Triptans [SEDA-36, 277]
  • Cardiovascular and Nervous System
  • Urinary Tract
  • Second Generation Effects
  • Pregnancy and Teratogenicity
  • Ginkgo biloba [SEDA-36, 276]
  • Tumorigenicity
  • Cytotoxicity and Mutagenicity
  • Genotoxicity
  • Hematologic
  • Drugs Used in the Treatment of Venous Disorders
  • Benzbromarone [SEDA-36, 276]
  • Liver
  • Diosmin
  • Cardiovascular
  • Other Peripheral Vasodilators
  • Phosphodiesterase Type 5 Inhibitors [SEDA-36, 277]
  • Sensory Systems
  • Liver
  • Immunologic
  • References
  • Chapter 20: Antihypertensive Drugs
  • Angiotensin-Converting Enzyme Inhibitors [SED-15, 226
  • SEDA-33, 416
  • SEDA-34, 321
  • SEDA-35,364, SEDA-36, 282]
  • General Information
  • Cardiovascular
  • Delapril
  • General Information
  • Lisinopril [SED-15, 2071
  • SEDA-33, 418
  • SEDA-34,324
  • SEDA-35, 367, SEDA-36, 282]
  • Mouth and Teeth
  • Drug Interactions
  • Angiotensin Receptor Blockers/Angiotensin II Receptor Antagonists [SEDA-15, 2071
  • SEDA-34, 324
  • SEDA-35
  • SEDA-36, 282]
  • General Information
  • Drug-Drug Interactions
  • Fimasartan [SEDA-36, 283]
  • Comparative Study
  • Irbesartan [SED-15, 1908
  • SEDA-32, 386
  • SEDA-36, 371]
  • Skin
  • Losartan [SED-15, 2168
  • SEDA-32, 387
  • SEDA-33, 419
  • SEDA-36, 371]
  • Genetic Factors
  • Olmesartan
  • Gastrointestinal
  • Drug Interactions
  • Valsartan [SEDA-36, 383]
  • Dermatological
  • Observational Study
  • Calcium Channel Blockers
  • Tumorigenicity
  • Direct Renin Inhibitors [SEDA-33, 420
  • SEDA-34, 328
  • SEDA-35, 373
  • SEDA-36, 283]
  • Aliskiren
  • Liver
  • Kidney
  • Drug-Drug Interaction
  • ACT-077825 (MK8151)
  • General Information
  • Direct Vasodilators [SEDA-36, 284]
  • Hydralazine [SEDA-33, 427
  • SEDA-34, 331
  • SEDA-35, 379
  • SEDA-36, 284]
  • Immunologic
  • Dopamine Beta-Hydroxylase Inhibitor
  • Etamicastat
  • General Information
  • Drugs That Act on the Sympathetic Nervous System [SEDA-33, 424
  • SEDA-34, 329
  • SEDA-35, 376
  • SEDA-36, 286]
  • Guanfacine
  • Drug Overdose
  • Methyldopa [SED-15, 2291
  • SEDA-33, 424
  • SEDA-34, 330
  • SEDA-35, 377
  • SEDA-36, 286]
  • Drug Overdose
  • Diuretics
  • Chlorthalidone
  • Renal Disease
  • Drug-Drug Interactions
  • Hydrochlorothiazide
  • Eyes
  • Electrolyte Balance
  • Skin
  • Tumerogenicity
  • Genetic Factors
  • Indapamide
  • Eyes
  • Triamterene
  • Kidney
  • Endothelian Receptor Antagonists
  • Ambrisentan [SEDA-33, 421
  • SEDA-34, 328
  • SEDA-35, 374
  • SEDA-36, 284]
  • Eyes
  • Prostacyclin Analog
  • Treprostinil Diolamine
  • Hepatic Disease
  • Infection Risk
  • Pulmonary Vasodilators [SEDA-33, 421
  • SEDA-34, 328
  • SEDA-35, 374
  • SEDA-36, 284]
  • Observational Study
  • Antihypertensives in Pregnancy
  • Observational Study
  • Genetic Factors
  • References
  • Chapter 21: Diuretics
  • Carbonic Anhydrase Inhibitors [SEDA-15, 643
  • SEDA-34, 339
  • SEDA-35, 387, SEDA-36, 289]
  • Acetazolamide
  • Eyes
  • Dermatology
  • Respiratory
  • Loop Diuretics [SEDA-15, 567, 1454
  • SEDA-34, 342
  • SEDA- 35, 390
  • SEDA-36, 290]
  • Azosemide
  • Urinary System
  • Bumetanide
  • Urinary System
  • Ethacrynic Acid
  • Electrolyte
  • Pharmacodynamics
  • Furosemide
  • Thrombocytopenia
  • Urinary System
  • Electrolytes
  • Torsemide
  • Contrast-Induced Acute Kidney Injury
  • Thiazide and Thiazide-Like Diuretics [SEDA-15, 3375
  • SEDA-34, 340
  • SEDA-35, 388
  • SEDA-36, 292]
  • Chlorothiazide
  • Metabolic
  • Chlorthalidone
  • Hemodynamics
  • Hydrochlorothiazide
  • Electrolyte Balance-Hyponatremia
  • Electrolyte Balance-Hypercalcemia
  • Pharmacogenomics
  • Metabolic
  • Skin
  • Indapamide
  • Eyes
  • Aldosterone Receptor Antagonists
  • Eplerenone [SEDA-15, 1227
  • SEDA-34, 344
  • SEDA-35, 391
  • SEDA-36, 293]
  • Electrolyte Balance
  • Drug-Drug Interactions
  • Spironolactone [SEDA-15, 3176
  • SEDA-34, 345
  • SEDA-35, 392
  • SEDA-36, 292]
  • Urinary System
  • Gynecomastia
  • Gynecological Cancers
  • Osmotic Diuretics
  • Mannitol [SEDA-15, 2203
  • SEDA-34, 346
  • SEDA-35, 393
  • SEDA-36, 294]
  • Urinary System
  • Respiratory System
  • References
  • Chapter 22: Metals
  • Aluminium [SED-15, 97
  • SEDA-32, 413
  • SEDA-33, 447
  • SEDA-34, 349
  • SEDA-35, 397
  • SEDA-36, 297]
  • Biological Monitoring
  • Management of Adverse Reactions
  • Nervous System
  • Cardiovascular System
  • Arsenic [SED-15, 339
  • SEDA-32, 414
  • SEDA-33, 448
  • SEDA-34, 351
  • SEDA-35, 399
  • SEDA-36, 298]
  • Genotoxicity
  • Systematic Reviews and Studies
  • Pregnancy
  • Nervous System
  • Skin
  • Cardiovascular System
  • Biomonitoring
  • Susceptibility
  • Cancer
  • Antimony and Antimonials [SED-15, 316
  • SEDA-32, 414
  • SEDA-33, 448
  • SEDA-34, 350
  • SEDA-35, 398
  • SEDA-36, 298]
  • Nervous System
  • Observational Study
  • Beryllium [SEDA-34, 353
  • SEDA-35, 400
  • SEDA-36, 301]
  • Calcium Salts [SED-15, 610
  • SEDA-33, 449
  • SEDA-34, 354
  • SEDA-35, 400
  • SEDA-36, 301]
  • Systematic Reviews and Studies
  • Observational Study
  • Cancer
  • Pregnancy
  • Chromium [SED-15, 737
  • SEDA-32, 414
  • SEDA-33, 450
  • SEDA-34, 354
  • SEDA-35, 401
  • SEDA-36, 303]
  • Cancer
  • Systematic Reviews and Studies
  • Genotoxicity
  • Cobalt [SED-15, 847
  • SEDA-32, 415
  • SEDA-33, 450
  • SEDA-34, 354
  • SEDA-35, 402
  • SEDA-36, 303]
  • Systematic Reviews
  • Multiorgan Dysfunctions
  • Copper [SED-15, 901
  • SEDA-32, 415
  • SEDA-33, 450
  • SEDA-34, 355
  • SEDA-35, 402
  • SEDA-36, 304]
  • Cytotoxicity
  • Nervous System
  • Gold and Gold Salts [SED-15, 1520
  • SEDA-32, 416
  • SEDA-33, 451
  • SEDA-34, 355
  • SEDA-35, 402
  • SEDA-36, 305]
  • Lanthanum Carbonate [SEDA-32, 417
  • SEDA-33, 451
  • SEDA-34, 356
  • SEDA-35, 404
  • SEDA-36, 306]
  • Lead [SED-15, 2013
  • SEDA-28, 247
  • SEDA-35, 404
  • SEDA-36, 307]
  • Fetotoxicity
  • Monitoring Therapy
  • Reproductive System
  • Iron Salts [SED-15, 1911
  • SEDA-32, 417
  • SEDA-33, 451
  • SEDA-34, 355
  • SEDA-35, 402
  • SEDA-36, 305]
  • GI Tract
  • Magnesium Salts [SED-15, 2196
  • SEDA-32, 417
  • SEDA-33, 452
  • SEDA-34, 356
  • SEDA-35, 406
  • SEDA-36, 309]
  • Mercury and Mercurial Salts [SED-15, 2259
  • SEDA-32, 419
  • SEDA-33, 453
  • SEDA-34, 358
  • SEDA-35, 407
  • SEDA-36, 311]
  • Nervous System
  • Cardiovascular System
  • Nickel [SED-15, 2502
  • SEDA-32, 419
  • SEDA-33, 453
  • SEDA-34, 358
  • SEDA-35, 409
  • SEDA-36, 313]
  • Genotoxicity
  • Respiratory System
  • Skin
  • Immunologic
  • Biological Monitoring
  • Potassium Salts [SED-15, 2905
  • SEDA-31, 392
  • SEDA-35, 409
  • SEDA-36, 314]
  • Observational Study
  • Diagnosis of Adverse Effects of Drugs
  • Strontium Salts [SEDA-32, 420
  • SEDA-33, 455
  • SEDA-34, 359
  • SEDA-35, 410
  • SEDA-36, 315]
  • Cardiovascular System
  • Silver Salts and Derivatives [SED-15, 3140
  • SEDA-32, 420
  • SEDA-33, 454
  • SEDA-34, 359
  • SEDA-35, 409
  • SEDA-36, 314]
  • Titanium [SED-15, 3434
  • SEDA-32, 420
  • SEDA-33, 456
  • SEDA-34, 360
  • SEDA-35, 410
  • SEDA-36, 315]
  • Systematic Reviews
  • Zinc [SED-15, 3717
  • SEDA-32, 420
  • SEDA-33, 458
  • SEDA-34, 360
  • SEDA-35, 410
  • SEDA-36, 315]
  • Observational Study
  • Respiratory Effect
  • References
  • Chapter 23: Metal Antagonists
  • Introduction
  • Deferasirox [SEDA-32, 426
  • SEDA-33, 466
  • SEDA-34, 368
  • SEDA-35, 420
  • SEDA-36, 323]
  • Organs and Systems
  • Cardiovascular
  • Respiratory
  • Nervous System
  • Sensory Systems
  • Metabolism
  • Hematologic
  • Gastrointestinal
  • Liver
  • Urinary Tract
  • Skin
  • Immunologic
  • Body Temperature
  • Long-Term Effects
  • Genotoxicity
  • Susceptibility Factors
  • Age
  • Deferiprone [SEDA-15, 1054
  • SEDA-32, 427
  • SEDA-33, 468
  • SEDA-34, 370
  • SEDA-35, 422, SEDA-36, 327]
  • Organs and Systems
  • Cardiovascular
  • Nervous System
  • Neuromuscular Function
  • Musculoskeletal
  • Susceptibility Factors
  • Age
  • Deferoxamine/Desferrioxamine [SEDA-15, 1058
  • SEDA-32, 429
  • SEDA-33, 471
  • SEDA-34, 371, SEDA-35, 423]
  • Organs and Systems
  • Sensory Systems
  • Urinary Tract
  • Immunologic
  • Infection Risk
  • Long-Term Effects
  • Tumorigenicity
  • Susceptibility Factors
  • Age
  • Edetic Acid (EDTA) [SED-15, 1300
  • SEDA-31, 405
  • SEDA-32, 431
  • SEDA-33, 474
  • SEDA-35, 372]
  • HQK-1001 (2,2-Dimethylbutyrate)
  • Hydroxyurea [SEDA-36, 330]
  • Organs and Systems
  • Endocrine
  • Hematologic
  • Gastrointestinal
  • Skin
  • Reproductive System
  • Immunologic
  • D-Penicillamine [SEDA-15, 2729
  • SEDA-32, 430
  • SEDA-33, 472
  • SEDA-34, 372
  • SEDA-35, 424
  • SEDA-36, 330]
  • Organs and Systems
  • Respiratory
  • Nervous System
  • Gastrointestinal
  • Liver
  • Urinary Tract (Kidney)
  • Skin
  • Trientine (Triethylenetetramine) [SEDA-15, 3508
  • SEDA-32, 431, SEDA-33, 474
  • SEDA-34, 373
  • SEDA-35, 427
  • SEDA-36, 333]
  • Tiopronin [SED-15, 3430
  • SEDA-35, 373]
  • Organs and Systems
  • Urinary Tract (Kidney)
  • Polystyrene Sulphonates [SEDA-15, 2894
  • SEDA-32, 433
  • SEDA-33, 474
  • SEDA-34, 373
  • SEDA-35, 427
  • SEDA-36, 333]
  • Sodium Polystyrene Sulfonate (Kayexalate)
  • Organs and Systems
  • Gastrointestinal
  • References
  • Chapter 24: Antiseptic Drugs and Disinfectants
  • All Commonly Used Antiseptics and Disinfectants
  • Infection Risk
  • Aldehydes [SED-15, 1439, 1513
  • SEDA-31, 409
  • SEDA-32, 437
  • SEDA-33, 479
  • SEDA-34, 377
  • SEDA-36, 339]
  • Formaldehyde
  • Respiratory
  • Gastrointestinal
  • Tumorigenicity
  • Immunologic
  • Glutaraldehyde (Glutaral)
  • Gastrointestinal
  • Immunologic
  • Guanidines
  • Chlorhexidine [SED-15, 714
  • SEDA-31, 410
  • SEDA-32, 439
  • SEDA-33, 480
  • SEDA-34, 378
  • SEDA-36, 340]
  • Drug Formulations
  • Skin
  • Immunologic
  • Polyhexamethylene Guanidine [SEDA-36, 341]
  • Respiratory
  • Polyhexamethylene Biguanidine [SEDA-36, 341]
  • Immunologic
  • Benzalkonium Compounds [SED-15, 421
  • SEDA-32, 440
  • SEDA-33, 481
  • SEDA-34, 379
  • SEDA-36, 341]
  • Sensory Systems
  • Ethylene Oxide [SED-15, 1296
  • SEDA-29, 242
  • SEDA-34, 379
  • SEDA-36, 341]
  • Tumorigenicity
  • Triclosan [SEDA-34, 379, SEDA-36, 342]
  • Tumorigenicity
  • Fertility
  • Endocrine
  • Immunologic
  • Respiratory
  • Halogens
  • Sodium Hypochlorite [SED-15, 3157
  • SEDA-28, 262
  • SEDA-34, 380
  • SEDA-36, 342]
  • Teeth
  • Skin
  • Urinary Tract
  • Iodophors [SED-15, 1896
  • SEDA-31, 411
  • SEDA-32, 440
  • SEDA-33, 485
  • SEDA-34, 380
  • SEDA-36, 342]
  • Iodine
  • Endocrine
  • Polyvinylpyrrolidone (Povidone) and Povidone-Iodine
  • Breasts
  • Musculoskeletal
  • Sensory Systems
  • Skin
  • Immunologic
  • References
  • Chapter 25: Beta-Lactams and Tetracyclines
  • Carbapenems
  • Ertapenem
  • Organs and Systems
  • Nervous System
  • Skin
  • Meropenem
  • General Adverse Drug Reactions
  • Interactions
  • Drug-Drug Interactions
  • Cephalosporins
  • General Information
  • Cefazolin
  • Organs and Systems
  • Drug Administration
  • Cefepime
  • Organs and Systems
  • Gastrointestinal
  • Nervous System
  • Cefozopran
  • Organs and Systems
  • Skin
  • Ceftaroline
  • Organs and Systems
  • Gastrointestinal
  • Hematologic
  • Lung
  • Renal
  • Skin
  • Ceftriaxone
  • Organs and Systems
  • Drug Administration
  • Drug Interactions
  • Gastrointestinal
  • Hematologic
  • Hypersensitivity
  • Neurologic
  • Renal
  • Cefuroxime
  • Organs and Systems
  • Sensory Systems
  • Death
  • Cephalexin
  • Organs and Systems
  • Immunologic
  • Monobactams
  • Aztreonam
  • Organs and Systems
  • Hypersensitivity
  • Penicillins
  • Amoxicillin
  • Organs and Systems
  • Cardiology
  • Biliary Tract
  • Skin
  • Immunologic
  • Penicillin
  • Organs and Systems
  • Sensory Systems
  • Hematologic
  • Urinary Tract
  • Skin
  • Tetracyclines and Glycylcyclines
  • Doxycycline
  • Organs and Systems
  • Nervous System
  • Psychiatric
  • Metabolism
  • Gastrointestinal
  • Skin
  • Minocycline
  • Organs and Systems
  • Sensory Systems
  • Mouth and Teeth
  • Immunologic
  • Tetracycline
  • Organs and Systems
  • Gastrointestinal
  • Tigecycline
  • Organs and Systems
  • Hematologic
  • References
  • Chapter 26: Miscellaneous Antibacterial Drugs
  • Aminoglycosides [SED-15, 118
  • SEDA-32, 461
  • SEDA-33, 509
  • SEDA-34, 399
  • SEDA 35, 463
  • SEDA-36, 363]
  • Pharmacogenomics
  • Amikacin [SED-15, 111
  • SEDA-32, 461
  • SEDA-33, 510
  • SEDA-34, 400
  • SEDA-35, 463
  • SEDA-36, 363]
  • Sensory Systems
  • Urinary Tract
  • Respiratory
  • Pediatric
  • Gentamicin [SED-15, 1500
  • SEDA-32, 461
  • SEDA-33, 510
  • SEDA-34, 400
  • SEDA-35, 463
  • SEDA-36, 364]
  • Urinary Tract
  • Tobramycin [SED-15, 3437
  • SEDA-32, 463
  • SEDA-33, 513
  • SEDA-35, 464
  • SEDA-36, 365]
  • Pediatrics
  • Fluoroquinolones [SEDA-15, 1396
  • SEDA-32, 464
  • SEDA-33, 514
  • SEDA-34, 401
  • SEDA-36, 464
  • SEDA-36, 365]
  • Endocrine
  • Nervous System
  • Liver
  • Sensory System
  • Ciprofloxacin [SED-15, 783
  • SEDA-32, 465
  • SEDA-33, 514
  • SEDA-34, 402
  • SEDA-35, 465
  • SEDA-36, 365]
  • Drug-Drug Interaction
  • Electrolyte Balance
  • Autocoids
  • Musculoskeletal
  • Psychiatric
  • Sensory System
  • Levofloxacin [SED-15, 2047
  • SEDA-32, 467
  • SEDA-33, 516
  • SEDA-34, 403
  • SEDA-35, 465
  • SEDA-36, 366]
  • Pediatric
  • Endocrine
  • Nervous System
  • Musculoskeletal
  • Pharmacogenomics
  • Moxifloxacin [SED-15, 2392
  • SEDA-32, 468
  • SEDA-33, 518
  • SEDA-34, 404
  • SEDA-35, 466
  • SEDA-36, 367]
  • Sensory Systems
  • Pharmacogenomics
  • Ofloxacin [SED-15, 2597
  • SEDA-34, 405
  • SEDA-35, 466
  • SEDA-36, 368]
  • Pediatric
  • Glycopeptides [SEDA-32, 469
  • SEDA-33, 519
  • SEDA-34, 405
  • SEDA-35, 466, SEDA-36, 368]
  • Dalbavancin
  • Drug Studies
  • Oritavancin
  • Drug Studies
  • Teicoplanin [SED-15, 3305
  • SEDA-32, 469
  • SEDA-33, 519
  • SEDA-34, 405
  • SEDA-35, 467
  • SEDA, 368]
  • Drug Studies
  • Skin
  • Telavancin [SEDA-33, 520
  • SEDA-34, 405
  • SEDA-35, 467
  • SEDA, 369]
  • Drug Studies
  • Vancomycin [SED-15, 3593
  • SEDA-32, 470
  • SEDA-33, 520
  • SEDA-34, 406
  • SEDA-35, 467
  • SEDA-36, 369]
  • Urinary Tract
  • Hematologic
  • Immunologic
  • Ketolides [SED-15, 1976
  • SEDA-32, 471
  • SEDA-33, 521
  • SEDA-34, 407
  • SEDA-35, 469
  • SEDA-36, 370]
  • Solithromycin [SEDA-35, 469
  • SEDA-36, 370]
  • Telithromycin [SEDA-35, 469
  • SEDA-36, 371]
  • Lincosamides [SED-15, 2063
  • SEDA-32, 472
  • SEDA-33, 522
  • SEDA-34, 407
  • SEDA-35, 469
  • SEDA-36, 371]
  • Clindamycin
  • Urinary Tract
  • Macrolides [SED-15, 2183
  • SEDA-32, 472
  • SEDA-33, 522
  • SEDA-34, 408
  • SEDA-35, 469
  • SEDA-36, 371]
  • Azithromycin [SED-15, 389
  • SEDA-33, 522
  • SEDA-34, 408
  • SEDA-35, 469
  • SEDA-36, 371]
  • Cardiovascular
  • Sensory Systems
  • Clarithromycin [SED-15, 799
  • SEDA-32, 473
  • SEDA-33, 523
  • SEDA-34, 408
  • SEDA-35, 470
  • SEDA-36, 372]
  • Drug-Drug Interactions
  • Psychiatric
  • Cardiovascular
  • Psychiatric
  • Gastrointestinal
  • Erythromycin [SED-15, 1237
  • SEDA-32, 474
  • SEDA-33, 523
  • SEDA-34, 409
  • SEDA-35, 470
  • SEDA-36, 373]
  • Cardiovascular
  • Oxazolidinones [SED-15, 2645
  • SEDA-32, 474
  • SEDA-33, 525
  • SEDA-34, 409
  • SEDA-35, 471
  • SEDA-36, 373]
  • Linezolid [SEDA-35, 469
  • SEDA-36, 373]
  • Hematologic
  • Drug-Drug Interactions
  • Acid Base Balance
  • Endocrine
  • Sensory System
  • Tedizolid
  • Drug Studies
  • Polymyxins [SED-15, 2891
  • SEDA-32, 476
  • SEDA-33, 527
  • SEDA-34, 412
  • SEDA-35, 473
  • SEDA-36, 374]
  • Colistin [SEDA-35, 473
  • SEDA-36, 374]
  • Respiratory
  • Streptogramins [SED-15, 3182
  • SEDA-32, 528
  • SEDA-34, 413
  • SEDA-35, 473
  • SEDA-36, 375]
  • Pristinamycin [SEDA-34, 413
  • SEDA-35, 469
  • SEDA-36, 375]
  • Trimethoprim and Co-Trimoxazole [SED-15, 3216, 3510
  • SEDA-32, 477
  • SEDA-33, 528
  • SEDA-34, 414
  • SEDA-35, 474
  • SEDA-36, 375]
  • Trimethoprim-Sulfamethoxazole [SEDA-35, 474
  • SEDA-36, 375]
  • Musculoskeletal
  • Electrolyte Balance
  • Psychiatric
  • Other Antimicrobial Drugs
  • Daptomycin [SED-15, 1053
  • SED-32, 478
  • SEDA-33, 529
  • SEDA-34, 416
  • SEDA-35, 474
  • SEDA-36, 375]
  • Musculoskeletal
  • Immunologic
  • Fosfomycin [SED-15, 1448
  • SEDA-34, 417
  • SEDA-35, 476
  • SEDA-36, 376]
  • Fusidic Acid [SED-15, 1460
  • SEDA-32, 479
  • SEDA-33, 530
  • SEDA-34, 417
  • SEDA-35, 475
  • SEDA-36, 376]
  • References
  • Chapter 27: Antifungal Drugs
  • Allylamines [SEDA-34, 427
  • SEDA-35,483
  • SEDA-36, 381]
  • Terbinafine [SEDA-34, 427
  • SEDA-35,483
  • SEDA-36, 381]
  • Immunology/Liver
  • Skin
  • Drug-Drug Interactions
  • Metoprolol
  • Perhexiline
  • Pharmacogenomics
  • Amphotericin [SEDA-33, 542
  • SEDA-34, 427
  • SEDA-35,483
  • SEDA-36, 382]
  • Adverse Event Comparison of Available Amphotericin Formulations
  • Amphotericin Lipid Complex (ABLC)
  • Respiratory
  • Liposomal Amphotericin (L-AmB)
  • Sensory Systems
  • Cardiovascular
  • Immunology
  • Antifungal Azoles [SEDA-33, 545
  • SEDA-34, 428
  • SEDA-35, 484
  • SEDA-36, 382]
  • Adverse Event Comparison of Available Azole Antifungals
  • Fluconazole [SEDA-33, 551
  • SEDA-34, 430
  • SEDA-35,485
  • SEDA-36, 382]
  • Skin
  • Itraconazole [SED-15, 1969
  • SEDA-33, 552
  • SEDA-34, 430
  • SEDA-35,485
  • SEDA-36, 383]
  • Cardiovascular
  • Ketoconazole [SEDA-34, 430
  • SEDA-35,486
  • SEDA-36, 383]
  • Hepatic
  • Luliconazole
  • Posaconazole [SEDA-33, 553
  • SEDA-34, 430
  • SEDA-35, 486
  • SEDA-36, 383]
  • Voriconazole [SEDA-33, 554
  • SEDA-34, 431
  • SEDA-35,486
  • SEDA-36, 384]
  • Hair/Nails
  • Sensory System
  • Cardiovascular System
  • Liver
  • Skin
  • Periostitis
  • Periostitis: Cases
  • Drug-Drug Interactions and Pharmacogenomics of the Azoles Antifungals
  • Apixaban
  • Corticosteroids
  • Rivaroxaban
  • Warfarin
  • Vincristine
  • Pyrimadine Analogues [SEDA-36, 383]
  • Flucytosine
  • Echinocandins [SEDA-33,556
  • SEDA-34,434
  • SEDA-35,489
  • SEDA-36, 388]
  • Cardiac Effects of the Echinocandins
  • Anidulafungin [SEDA-35,489
  • SEDA-36, 388]
  • Hair/Nails
  • Caspofungin [SEDA-33, 556
  • SEDA-34, 434
  • SEDA-35,490
  • SEDA-36, 389]
  • Eosinophilia
  • References
  • Chapter 28: Antiprotozoal Drugs
  • Introduction
  • Albendazole
  • Drug-Interaction
  • Artemether-Lumefantrine
  • Dihydroartemisinin-Piperaquine
  • Dihydroartemisinin
  • Piperaquine
  • Fexinidazole
  • Fumagillin
  • Nitazoxanide
  • Oxantel Pamoate-Albendazole
  • Posaconazole
  • Primaquine
  • Quinacrine
  • Tafenoquine-Chloroquine
  • Thiamine Hydrochloride
  • Trimethoprim-Sulfamethoxazole
  • Drug-Interaction
  • Artesunate
  • Mefloquine
  • Acetazolamide
  • References
  • Chapter 29: Antiviral Drugs
  • Drugs Active Against Cytomegalovirus
  • Cidofovir [SED-15, 771
  • SEDA-32, 529
  • SEDA-33, 577
  • SEDA-34, 447, SEDA-35, 503
  • SEDA-36, 401]
  • Observational Studies
  • Dermatological Studies
  • Foscarnet [SED-15 1447, SEDA-34 448, SEDA-35, 504, SEDA-36, 403]
  • Observational Study
  • Ganciclovir and Valganciclovir [SED-15, 1480
  • SEDA-34, 449, SEDA-35, 504, SEDA-36, 404]
  • Observational Study
  • Neurological Studies
  • Combination Study
  • Drugs Active Against Herpes Viruses [SEDA-32, 530
  • SEDA-33, 577
  • SEDA-34, 450, SEDA-35, 507, SEDA-36, 407]
  • Acyclovir
  • Nervous System
  • Renal Function
  • Famciclovir
  • Renal Function
  • Skin Lesions
  • Neurological
  • Valaciclovir
  • Comparative Studies
  • Neurological
  • Drugs Active Against Hepatitis Viruses
  • Adefovir [SED-15, 35
  • SEDA-32, 530
  • SEDA-33, 578
  • SEDA-34, 452
  • SEDA-35, 507
  • SEDA-36, 409]
  • Urinary Tract
  • Comparative Study
  • Direct-Acting Antiviral Protease Inhibitors [SEDA-35, 508
  • SEDA-36, 409]
  • Boceprevir
  • Acute Pancreatitis
  • Drug-Drug Interactions
  • Telaprevir
  • Combination
  • Liver Function
  • Skin
  • Entecavir [SEDA-33, 578, SEDA-34, 452, SEDA-35 512
  • SEDA-36, 411]
  • Observational Study
  • Ribavirin [SEDA-33, 578
  • SEDA-34, 452, SEDA-35, 512
  • SEDA-36, 412]
  • Telbivudine [SEDA-33, 582
  • SEDA-34, 455
  • SEDA-35, 515
  • SEDA-36, 412]
  • Neurological
  • Faldaprevir
  • Sofosbuvir
  • Simeprevir
  • Drugs Active Against Human Immunodeficiency Virus: Combinations
  • Fixed Dose Combination Antiretrovirals
  • Abacavir/Lamivudine
  • Observational Study
  • Abacavir/Lamivudine/ZDV
  • Observational Study
  • New Component Drugs
  • Elvitegravir (Formerly GS-9137)
  • Cobicistat (Formerly GS-9350)
  • Observational Study
  • Elvitegravir
  • Cobicistat
  • Observational Studies
  • Elvitegravir/Cobicistat/FTC/Tenofovir
  • Drugs Active Against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SED-15, 258...
  • Abacavir [SED-15, 3
  • SEDA-32, 534
  • SEDA-33, 585
  • SEDA-34, 456
  • SEDA-35, 516
  • SEDA-36, 415]
  • Didanosine [SED-15, 1113
  • SEDA 32, 535
  • SEDA-33, 587
  • SEDA-35, 516
  • SEDA-36, 416]
  • Emtricitabine [SEDA-35, 517
  • SEDA-36, 416]
  • Lamivudine [SED-15, 1989
  • SEDA-32, 531
  • SEDA-33, 587
  • SEDA-34, 456
  • SEDA-35, 517
  • SEDA-36, 416]
  • Observational Studies
  • Stavudine (D4T) [SED-15, 3180
  • SEDA-32, 535
  • SEDA-33, 587
  • SEDA-34, 456, SEDA-35, 517
  • SEDA-36, 417]
  • Observational Studies
  • Zidovudine [SED-15, 3713
  • SEDA-32, 536
  • SEDA-33, 588
  • SEDA-34, 458
  • SEDA-35, 517
  • SEDA-36, 417]
  • Drugs Active Against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors
  • Tenofovir [SED-15, 3314
  • SEDA-32, 537
  • SEDA-33, 588
  • SEDA-34, 458
  • SEDA-35, 518
  • SEDA-36, 418]
  • Drugs Active Against Human Immunodeficiency Virus: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SED-15, 2553
  • S...
  • Efavirenz [SED-15, 1204
  • SEDA-32, 537
  • SEDA-33, 590
  • SEDA 34, 459
  • SEDA-35, 519
  • SEDA-36, 420]
  • Observational Studies
  • Genetic Variation
  • Etravirine [SEDA-33, 592
  • SEDA-34, 459
  • SEDA-35, 520
  • SEDA-36, 421]
  • Nevirapine [SEDA-33, 593
  • SEDA-34, 460
  • SEDA-35, 521
  • SEDA-36, 421]
  • Comparative Study
  • Observational Study
  • Rilpivirine [SEDA-35, 521
  • SEDA-36, 423]
  • Drugs Active Against Human Immunodeficiency Virus: Protease Inhibitors [SED-15, 2586
  • SEDA-32, 541
  • SEDA-33, 593
  • SEDA-34, ...
  • Fosamprenavir/Amprenavir
  • Experimental Study
  • Atazanavir
  • Darunavir
  • Nelfinavir
  • Drug-Drug Interactions
  • Ritonavir
  • Saquinavir
  • Drugs Active Against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-33
  • 598
  • SEDA-34, 464
  • SEDA-35, 525
  • SEDA...
  • Enfuvirtide
  • Drugs Active Against Human Immunodeficiency Virus: Integrase Inhibitors [SEDA-33, 599, SEDA-34, 465, SEDA-35, 525
  • SEDA-36,...
  • Dolutegravir
  • Observational Studies
  • Raltegravir
  • Observational Study
  • Musculoskeletal
  • Drugs Active Against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-33, 600
  • SEDA 34, 465
  • SEDA-35...
  • Maraviroc
  • Drugs Active Against Influenza Viruses: Ion Channel Inhibitors [SED-15, 105, 3051
  • SEDA-32, 544
  • SEDA-33, 269, 602
  • SEDA-34...
  • Amantadine
  • Drugs Active Against Influenza Viruses: Neuraminidase Inhibitors [SED-15, 2436
  • SEDA-32, 544
  • SEDA-33, 601
  • SEDA-34, 466
  • S...
  • Oseltamivir (Tamiflu)
  • Other Drugs
  • Imiquimod [SED-15, 1718
  • SEDA-35, 530
  • SEDA-36, 431]
  • Dermatological Studies
  • References
  • Chapter 30: Drugs Used in Tuberculosis and Leprosy
  • Rifamycins
  • Rifampicin
  • Urinary Tract
  • Immunologic
  • Hepatic
  • Drug-Drug Interactions
  • Rifabutin (RBT)
  • Drug-Drug Interactions
  • Latent TB Infection
  • Rifapentine
  • Bedaquiline
  • Linezolid
  • Hematologic
  • Hematologic
  • Sensory Systems
  • Isoniazid
  • Hepatotoxicity
  • Genetic Susceptibility
  • Gastrointestinal and Dermatological
  • Neurotoxicity
  • Psychiatry
  • Autoimmune Disorders
  • Tenosynovitis
  • Ethambutol
  • Visual Impairment
  • Genetic Predisposition
  • Hypersensitivity Reactions
  • Fluoroquinolones
  • Pyrazinamide
  • Photosensitivity
  • Hematology
  • Clofazimine
  • Cycloserine
  • Psychiatric
  • Delamanid
  • Dapsone
  • Genetic Susceptibility
  • Streptomycin
  • References
  • Chapter 31: Antihelminthic Drugs
  • Albendazole (SEDA-31, 508
  • SEDA-32, 572
  • SEDA-33, 647
  • SEDA-36, 458)
  • Observational Studies
  • Comparative Studies
  • Drug Combination Studies
  • Placebo-Controlled Studies
  • Liver
  • Case Study1
  • Inhibition of Microtubule-Related Cellular Functions After Long-Term High Dose Exposure to Albendazole
  • Case Study2
  • Recurrent Acute Hepatitis due to Single Dose of Albendazole in a Child
  • Case Study3
  • Recurrent Acute Hepatitis due to Repeated Ingestion of Albendazole
  • Case Study4
  • Granulomatous Hepatitis in an Adult Resulting from Albendazole
  • Case Study5
  • Toxic Hepatitis in an Adult Induced by Albendzole
  • Case Study6
  • Hepatitis in an Adult Caused by Continuous Albendazole Therapy
  • Case Study7
  • Acute Hepatitis due to Repeat Treatment with Albendazole in a Patient with Chronic Toxocara Canis Infection
  • Renal System
  • Acute Renal Failure due to Albendazole Therapy
  • Ivermectin (SEDA-31, 509
  • SEDA-32, 575
  • SEDA-33, 649
  • SEDA-36, 460)
  • Comparative Studies
  • Nervous System
  • Levamisole (SEDA-31, 510
  • SEDA-32, 575
  • SEDA-33, 649
  • SEDA-36, 460)
  • Nervous System
  • Levamisole-Contaminated Cocaine
  • Cardiovascular
  • Skin
  • Case Study
  • Pyoderma Gangrenosum in a Cocaine User [27A]
  • Case Study
  • Leg Ulceration
  • Case Study
  • Facial Cutaneous Necrosis due to Levamisole Toxicity in a Cocaine User
  • Hair
  • Case Study
  • Detection of Levamisole in Hair Samples of a Patient with Panniculitis Secondary to Abuse of Levamisole-Contaminated Cocaine
  • Immune
  • Case Study
  • Toxicity Mimicking Autoimmune Disease
  • Renal System
  • Case Study
  • Cases of Kidney Injury Resulting from Ingestion of Levamisole-Contaminated Cocaine
  • Death
  • Mebendazole (SEDA-36, 461)
  • Comparative Studies
  • Drug Combination Studies
  • Praziquantel (SEDA-31, 511
  • SEDA-33, 650
  • SEDA-36, 461)
  • Observational Studies
  • Comparative Studies
  • Drug Combination Studies
  • Systematic Reviews and Meta-Analyses
  • Tribendimidine (SEDA 36, 462)
  • Comparative Studies
  • References
  • Chapter 32: Vaccines
  • General [SEDA-36, 465]
  • Viral Vaccines
  • Hepatitis B Vaccine [SED-15, 3565, 3566, 3568
  • SEDA-36, 466]
  • Organ and Systems
  • Neuromuscular Function
  • Susceptibility Factors
  • Immunocompromised: HIV
  • Human Papillomavirus Vaccine [SEDA-34, 501
  • SEDA-35, 574
  • SEDA-36, 466]
  • General
  • Organs and Systems
  • Cardiovascular: Venous Thromboembolism
  • Nervous System: Acute Disseminated Encephalomyelitis
  • Nervous System: Autonomic Dysfunction
  • Nervous System: Chorea
  • Nervous System: Guillain-Barré Syndrome
  • Skin
  • Immunologic
  • Long-Term Effects
  • Susceptibility Factors
  • Immunocompromised: HIV
  • Drug Administration
  • Drug Formulations
  • Drug Dosage Regimens
  • Influenza Vaccines [SED-15, 3565, 3569
  • SEDA-34, 501
  • SEDA-35, 574
  • SEDA-36, 467]
  • Organs and Systems
  • Hematologic
  • Musculoskeletal
  • Nervous System
  • Skin
  • Vascular Diseases
  • Second-Generation Effects
  • Pregnancy
  • Susceptibility Factors
  • Age
  • Immunocompromised: Human Immunodeficiency Virus (HIV)
  • Immunocompromised: Cancer Patients Receiving Chemotherapy
  • Respiratory Diseases
  • Drug Administration
  • Drug Formulations: Quadrivalent Influenza Vaccine
  • Drug Administration: Dosage Regimen
  • Drug Administration Route: Intradermal
  • MMR Vaccine [SED-15, 3555, 3566, 3567, 3569
  • SEDA-34, 503
  • SEDA-35, 575
  • SEDA-36, 473]
  • Susceptibility Factors
  • Female Sex
  • Measles-Mumps-Rubella-Varicella Vaccine [SEDA-35, 575
  • SEDA-36, 474]
  • General
  • Rotavirus Vaccine [SED-15, 3554, 3555
  • SEDA-34, 504
  • SEDA-35, 576
  • SEDA-36, 473]
  • Organs and Systems
  • Gastrointestinal
  • Varicella Vaccine and Herpes Zoster Vaccine [SEDA-34, 506
  • SEDA-36, 474]
  • General
  • Organs and Systems
  • Ophthalmic
  • Skin
  • Infection Risk
  • Death
  • Susceptibility Factors
  • Immunocompromised: Transplant Patients
  • Elderly
  • Yellow Fever Vaccine [SEDA-34, 506
  • SEDA-35, 577
  • SEDA-36, 475]
  • General
  • Susceptibility Factors
  • Elderly
  • Japanese Encephalitis Vaccine [SEDA-34, 503
  • SEDA-35, 575
  • SEDA-36, 475]
  • General
  • Bacterial Vaccines
  • Meningococcal Vaccines [372
  • SEDA-36, 476]
  • General
  • Organs and Systems
  • Nervous System
  • Second-Generation Effects
  • Pregnancy
  • Interactions
  • Drug-Drug Interactions
  • Pneumococcal Vaccines [SEDA-36, 477]
  • General
  • Susceptibility Factors
  • Age: Adults & Elderly Adults
  • Autoimmune Disease: Systemic Lupus Erythematosus (SLE)
  • Hematologic Disease: Sickle Cell Disease
  • Immunocompromised: Rheumatoid Arthritis (RA)
  • Immunocompromised: Chronic Lymphocytic Leukemia (CLL)
  • Drug Administration
  • Drug Administration: Route
  • Interactions
  • Drug-Drug
  • Pertussis Vaccine (Including Diphtheria-Tetanus-Acellular Pertussis Vaccines) [SED-15, 3555, 3558, 3562, 3565, 3567, 3570
  • ...
  • General
  • Organs and Systems
  • Musculoskeletal
  • Skin
  • Second-Generation Effects
  • Pregnancy
  • Susceptibility Factors
  • Age & Sex: Adolescent Males
  • References
  • Chapter 33: Blood, Blood Components, Plasma, and Plasma Products
  • Albumin and Derivatives [SEDA-15, 54
  • SEDA-33, 670
  • SEDA-34, 509
  • SEDA-35, 583
  • SEDA-36, 483]
  • Albumin [SEDA-15, 54
  • SEDA-33, 670
  • SEDA-34, 509
  • SEDA-35, 583
  • SEDA-36, 483]
  • Comparative Studies
  • Systematic Reviews
  • Respiratory
  • Immunologic
  • Drug-Drug Interaction
  • Blood Transfusion [SEDA-15, 529
  • SEDA-34, 509
  • SEDA-35, 583, SEDA-36, 483]
  • Erythrocytes
  • Respiratory
  • Immunologic
  • Hemotologic
  • Death
  • Technology and Transfusions
  • Granulocytes
  • Observational Study
  • Platelets
  • Observational Studies
  • Allergic Reactions and Fever
  • Blood Substitutes [SEDA-33, 672
  • SEDA-34, 511
  • SEDA-35, 586
  • SEDA-36, 485]
  • Hemoglobin-Based Oxygen Carriers [SEDA-33, 672
  • SEDA-34, 511
  • SEDA-35, 586
  • SEDA SEDA-36, 485]
  • Comparative Studies
  • Plasma and Plasma Products [SEDA-15, 84
  • SEDA-34, 512
  • SEDA-35, 586, SEDA-36, 486]
  • a1-Antitrypsin
  • C1 Esterase Inhibitor Concentrate
  • Observational Studies
  • Dose Escalation Studies
  • Cryoprecipitate
  • Observational Study
  • Fresh Frozen Plasma [SEDA-34, 513
  • SEDA-35, 587
  • SEDA-36, 487]
  • Systemic Review
  • Plasma Substitutes [SEDA-33, 675
  • SEDA-34, 513
  • SEDA-35, 587
  • SEDA-36, 487]
  • Dextrans [SEDA-15, 1082
  • SEDA-33, 675
  • SEDA-34, 513
  • SEDA-35,587
  • SEDA-36, 487]
  • Hematologic
  • Etherified Starches [SEDA-15, 1237
  • SEDA-33, 675
  • SEDA-34, 513
  • SEDA-35, 587
  • SEDA-36, 487]
  • Comparative Studies
  • Systematic Reviews
  • Cardiovascular
  • Fluid Balance
  • Hematologic
  • Urinary Tract
  • Skin
  • Gelatin [SEDA-34, 514
  • SEDA-35, 584
  • SEDA 36-487]
  • Systematic Reviews
  • Globulins
  • Immunoglobulins [SEDA-15, 1719
  • SEDA-33, 677
  • SEDA-34, 514
  • SEDA-35, 588
  • SEDA-36, 488]
  • Intravenous Immunoglobulin
  • Observational Studies
  • Comparative Studies
  • Major Reviews
  • Hematologic
  • Urinary
  • Skin
  • Immunologic
  • Drug Formulations
  • Subcutaneous Immunoglobulin
  • Observational Study
  • Skin
  • Anti-D immunoglobulin
  • Comparative Studies
  • Immunologic
  • Drug Interactions
  • Coagulation Proteins [SEDA-15, 845
  • SEDA-33, 679
  • SEDA-34, 518
  • SEDA-36, 493]
  • Factor I
  • Systemic Review
  • Impact of Meals and Lab Levels
  • Factor II
  • Factor VIIa [SEDA-15, 1318
  • SEDA-34, 518
  • SEDA-35, 592
  • SEDA-36, 493]
  • Observational Studies
  • Thromboembolic Events (TEs)
  • Factor VIII [SEDA-15, 1319
  • SEDA-34, 518
  • SEDA-35, 592
  • SEDA-36, 494]
  • Neurologic
  • Factor IX [SEDA-15, 1324
  • SEDA-34, 518
  • SEDA-35, 592
  • SEDA-36, 494]
  • Drug Formulations
  • Factor IX Gene Therapy
  • Prothrombin Complex Concentrate [SEDA-34, 518
  • SEDA-35, 518
  • SEDA-36, 494]
  • Cardiac Surgery
  • Haematologic
  • von Willebrand Factor (VWF)/Factor VIII Concentrates [SEDA-34, 519
  • SEDA-35, 594
  • SEDA-36, 494]
  • Comparative Studies
  • Observational Study
  • Erythropoietin and Derivatives [SEDA-34, 520
  • SEDA-35, 594
  • SEDA-36, 494]
  • Systematic Reviews
  • Thrombopoietin and Receptor Agonists [SEDA-15, 3409
  • SEDA-36-495]
  • Observational Studies
  • Systematic Review
  • Hematologic
  • Skin
  • Pregnancy
  • Interference with Diagnostic Tests
  • Transmission of Infectious Agents Through Blood Donation [SEDA-34, 521
  • SEDA-35,596
  • SEDA-36, 495]
  • Bacteria
  • Virus
  • Prion
  • Stem Cells [SEDA-34, 522
  • SEDA-35, 597
  • SEDA-36, 496]
  • Endocrinology
  • Respiratory System
  • Cardiovascular System
  • References
  • Chapter 34: Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis
  • Coumarin Anticoagulants [SED-15, 983
  • SEDA-34, 541
  • SEDA-35, 617
  • SEDA-36, 529]
  • Cardiovascular
  • Heparins [SED-15, 1590
  • SEDA-34, 543
  • SEDA-35, 618
  • SEDA-36, 530]
  • Hematologic
  • Skin
  • Immunologic
  • Direct Thrombin Inhibitors [SED-15, 1142
  • SEDA-34, 544
  • SEDA-35, 619
  • SEDA-36, 531]
  • Dabigatran [SEDA-34, 544
  • SEDA-35, 620
  • SEDA-36, 531]
  • Cardiovascular
  • Hematologic
  • Direct Factor XA Inhibitors [SEDA-34, 546
  • SEDA-35, 620
  • SEDA-36, 532]
  • Rivaroxaban [SEDA-34, 546
  • SEDA-35, 620, SEDA-36, 532]
  • Cardiovascular
  • Hematologic
  • Thrombolytic Drugs [SEDA-15, 3402
  • SEDA-35, 621
  • SEDA-36, 532]
  • Alteplase [SEDA-34, 547
  • SEDA-35, 621
  • SEDA-36, 532]
  • Cardiovascular
  • Nervous System
  • Hematologic
  • Musculoskeletal
  • Drug-Drug Interaction
  • Streptokinase [SEDA-15, 62
  • SEDA-34, 547
  • SEDA-36, 533]
  • Hematologic
  • Eyes
  • Glycoprotein IIb-IIIa Inhibitors [SED-15, 2849
  • SEDA-33, 720
  • SEDA-34, 548
  • SEDA-35, 622]
  • Abciximab [SED-15, 2849
  • SEDA-34, 548
  • SEDA-35, 622]
  • Hematologic
  • Eptifibatide [SED-15, 2849
  • SEDA-34, 548
  • SEDA-35, 622
  • SEDA-36, 533]
  • Hematologic
  • Sex
  • Tirofiban [SED-15, 2849
  • SEDA-34, 547
  • SEDA-35, 621
  • SEDA-36, 533]
  • Hematologic
  • P2Y12 Receptor Antagonists [SED-15, 821
  • SEDA-34, 548
  • SEDA-35, 622
  • SEDA-36, 533]
  • Cangrelor
  • Cardiovascular
  • Hematologic
  • Clopidogrel [SED-15, 821
  • SEDA-34, 548
  • SEDA-35, 622
  • SEDA-36, 533]
  • Systematic Reviews
  • Hematologic
  • Skin
  • Musculoskeletal
  • Genetic Factors
  • Race Factors
  • Drug-Drug Interactions
  • Smoking
  • Prasugrel [SEDA-34, 549
  • SEDA-35, 624
  • SEDA-36, 535]
  • Review
  • Hematologic
  • Skin
  • Ticagrelor [SEDA-34, 541
  • SEDA-35, 617]
  • Review
  • Respiratory
  • Hematologic
  • Skin
  • Sex
  • Hemostatic Agents [SEDA-34, 549
  • SEDA-35, 624
  • SEDA-36, 536]
  • Tranexamic Acid [SEDA-34, 549
  • SEDA-35, 625
  • SEDA-36, 536]
  • Nervous System
  • Hematologic
  • Eyes
  • References
  • Chapter 35: Gastrointestinal Drugs
  • Acid-Impacting Agents
  • Antacids [SED-15, 243
  • SEDA-34, 555
  • SEDA-35, 633
  • SEDA-36, 539]
  • Drug-Drug Interaction, Nemonoxicin
  • Neoplasms
  • Histamine-2 Receptor Antagonists [SED-15, 1629
  • SEDA-34, 562
  • SEDA-35, 637
  • SEDA-36, 545]
  • Systematic Review
  • Cognition
  • Peritonitis
  • Vitamin B12 Deficiency
  • Proton-Pump Inhibitors [SED-15, 2973
  • SEDA-34, 563
  • SEDA-35, 638
  • SEDA-36, 535]
  • Bone/Mineral Metabolism
  • Cardiovascular
  • Clostridium difficile Infection
  • Drug-Drug Interaction, Cancer Chemotherapeutics
  • Drug-Drug Interaction, Clopidogrel
  • Drug-Drug Interaction, Mycophenolate
  • Drug-Drug Interaction, Tacrolimus
  • Hypomagnesemia
  • Immunologic/Hypersensitivity
  • Pneumonia
  • Vitamin B12 Deficiency
  • Anticonstipation and Prokinetic Agents
  • Domperidone [SED-15, 1178
  • SEDA-34, 556
  • SEDA-35,633
  • SEDA-36, 541]
  • Cardiovascular
  • Linaclotide [SEDA-35, 646]
  • Meta-Analysis
  • Lubiprostone [SEDA-35, 647
  • SEDA-36, 541]
  • Randomized Controlled Trial
  • Magnesium [SED-15, 2196
  • SEDA-34,569
  • SEDA-35, 645
  • SEDA-36, 553]
  • Drug-Drug Interaction, H2 Receptor Antagonists and PPIs
  • Metoclopramide [SED-15, 2317
  • SEDA-34, 557
  • SEDA-35, 634
  • SEDA-36, 542]
  • Update
  • Pharmacogenetics
  • Naloxegol
  • Update
  • Randomized Controlled Trial
  • Polyethylene Glycol [SEDA-34, 569
  • SEDA-35, 646
  • SEDA-36, 553]
  • Meta-Analysis
  • Prucalopride [SEDA-34, 557]
  • Meta-Analysis
  • Systematic Review
  • Sodium Picosulfate/Polyethylene Glycol [SEDA-34, 570]
  • Observational Study
  • Teduglutide
  • Randomized Controlled Trial
  • Systematic Review
  • Antidiarrheal and Antispasmotic Agents
  • Bismuth Salts [SED-15, 518
  • SEDA-36, 551]
  • Loperamide [SED-15, 2159
  • SEDA-34, 573]
  • Otilonium Bromide
  • Randomized Controlled Trial
  • Rifaximin
  • Systematic Review
  • Antiemetic Agents
  • Aprepitant [SEDA-34, 561
  • SEDA-35,636
  • SEDA-36, 544]
  • Update
  • Observational Study
  • Droperidol [SED-15, 1192]
  • Cardiovascular
  • Fosaprepitant [SEDA-34, 561
  • SEDA-35, 636]
  • Observational Studies
  • Netupitant/Palonosetron
  • Update
  • Randomized Controlled Trials
  • Ondansetron [SED-1365
  • SEDA-34, 560
  • SEDA-35, 635
  • SEDA-36, 544]
  • Cardiovascular
  • Pharmacogenetic
  • Palonosetron [SED-15, 1365
  • SEDA-34, 561
  • SEDA-35, 636
  • SEDA-36, 544]
  • Cardiovascular
  • Anti-inflammatory Agents
  • Aminosalicylates [SED-15, 138
  • SEDA-34, 571
  • SEDA-35, 647
  • SEDA-36, 555]
  • Thiopurines (Azathioprine, 6-Thioguanine, 6-Mercaptopurine)
  • Update
  • Cancer
  • Pharmacogenetics
  • Biologics
  • Update
  • Steroids
  • References
  • Chapter 36: Drugs That Act on the Immune System: Cytokines and Monoclonal Antibodies
  • Cytokines
  • Bone Morphogenic Proteins [SEDA-34, 579
  • SEDA-35, 659
  • SEDA-36, 561]
  • Musculoskeletal
  • Colony-Stimulating Factors [SEDA-32, 675
  • SEDA-33, 769
  • SEDA-34, 581
  • SEDA-36, 563]
  • Granulocyte Colony-Stimulating Factor [SEDA-33, 769
  • SEDA-35, 659
  • SEDA-36, 563]
  • Skin
  • Filgrastim [SEDA-36, 563]
  • Hematologic
  • Pegfilgrastim [SEDA-36, 563]
  • Musculoskeletal
  • Hematologic
  • Interferons [SEDA-32, 676
  • SEDA-33, 773
  • SEDA-34, 581
  • SEDA-35, 660
  • SEDA-36, 564]
  • Interferon Alfa [SEDA-32, 676
  • SEDA-33, 773
  • SEDA-34, 581
  • SEDA-36, 564]
  • Endocrine
  • Eye
  • Skin
  • Interferon Beta [SEDA-33, 776
  • SEDA-36, 566]
  • Skin
  • Hematologic
  • Immunologic
  • Urinary Tract
  • Interleukins [SEDA-33, 777
  • SEDA-34, 771
  • SEDA-36, 567]
  • Anakinra (Interleukin-1 Receptor Antagonist) [SEDA-32, 677
  • SEDA-33, 779
  • SEDA-34, 582]
  • Skin
  • Liver
  • Hematologic
  • Tumor Necrosis Factor Alfa (TNF-a) and Its Antagonists [SEDA-33, 779
  • SEDA-34, 583
  • SEDA-36, 568]
  • Skin
  • Adalimumab [SED-15, 2015
  • SEDA-32, 709
  • SEDA-33, 818
  • SEDA-34, 618
  • SEDA-35, 703
  • SEDA-36, 568]
  • Psychiatric
  • Respiratory
  • Nervous System
  • Urinary Tract
  • Skin
  • Infection Risk
  • Liver
  • Certolizumab [SED-15, 2402
  • SEDA-32, 710
  • SEDA-33, 819
  • SEDA-34, 622
  • SEDA-35, 704]
  • Eye
  • Respiratory
  • Etanercept [SED-15, 3148
  • SEDA-32, 712
  • SEDA-33, 820
  • SEDA-34, 626
  • SEDA-35, 705]
  • Observational Study
  • Endocrine
  • Renal
  • Skin
  • Respiratory
  • Nervous System
  • Urinary Tract
  • Eye
  • Infection Risk
  • Golimumab [SED-15, 3279
  • SEDA-32, 714
  • SEDA-33, 821
  • SEDA-34, 629
  • SEDA-35, 705]
  • Skin
  • Infliximab [SEDA-32, 716
  • SEDA-33, 824
  • SEDA-34, 632
  • SEDA-35, 707]
  • Retrospective Study
  • Gastrointestinal
  • Liver
  • Hematologic
  • Nervous System
  • Infection Risk
  • Teratogenicity
  • Respiratory
  • Skin
  • Monoclonal Antibodies
  • Abciximab [SEDA-35, 672]
  • Respiratory
  • Hematologic
  • Adalimumab-See above
  • Alemtuzumab [SEDA-34, 586
  • SEDA-35, 672
  • SEDA-36, 569]
  • Endocrine
  • Infection Risk
  • Bevacizumab [SEDA-34, 587
  • SEDA-36, 570]
  • Prospective Study
  • Phase 3 Trial
  • Meta-Analysis
  • Gastrointestinal
  • Cardiovascular
  • Urinary Tract
  • Skin
  • Nervous System
  • Respiratory
  • Liver
  • Infection Risk
  • Skin
  • Eye
  • Cetuximab [SEDA-34, 590
  • SEDA-35, 673]
  • Meta-Analysis
  • Skin
  • Gastrointestinal
  • Respiratory
  • Daclizumab [SEDA-34, 591
  • SEDA-35, 675
  • SEDA-36, 574]
  • Observational Study
  • Natalizumab [SEDA-34, 593
  • SEDA-35, 676
  • SEDA-36, 578]
  • Pregnancy
  • Hematologic
  • Skin
  • Nervous System
  • Ranibizumab [SEDA-34, 762
  • SEDA-35, 877
  • SEDA-36, 580]
  • Eye
  • Rituximab [SEDA-34, 594
  • SEDA-35, 678
  • SEDA-36, 581]
  • Liver
  • Skin
  • Cardiovascular
  • Tocilizumab [SEDA-35, 668
  • SEDA-36, 582]
  • Hematologic
  • Trastuzumab [SEDA-34, 595
  • SEDA-35, 680
  • SEDA-36, 582]
  • Cardiovascular
  • References
  • Chapter 37: Drugs that Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs
  • Belatacept [SEDA 34-609]
  • Comparative Studies
  • Infection Risk
  • Cyclophosphamide [SED-15, 1025
  • SEDA-34, 612
  • SEDA-35, 700
  • SEDA-36, 592]
  • Observational Studies
  • Comparative Studies
  • Cardiovascular
  • Central Nervous System
  • Electrolyte Balance
  • Hematologic
  • Liver
  • Immunologic
  • Special Reviews - Cyclosporine (Ciclosporin) [SED-15, 743
  • SEDA-34, 609
  • SEDA-35, 699
  • SEDA-36, 591]
  • Cardiovascular
  • Nervous System
  • Endocrine
  • Mouth and Teeth
  • Gastrointestinal
  • Liver
  • Urinary Tract
  • Hair
  • Drug Administration Route
  • Drug-Drug Interactions
  • Everolimus [SED-15, 1306
  • SEDA-34, 614
  • SEDA-35, 701
  • SEDA 36, 592]
  • Systematic Reviews
  • Observational Studies
  • Cardiovascular
  • Respiratory
  • Neuromuscular Function
  • Urinary Tract
  • Immunologic
  • Liver
  • Drug-Drug Interactions
  • Fingolimod [SEDA-34, 616
  • SEDA-35, 703
  • SEDA-36, 593]
  • Placebo-Controlled Studies
  • Cardiovascular
  • Ear, Nose, Throat
  • Hematologic
  • Skin
  • Infection Risk
  • Teratogenicity
  • Glatiramer [SEDA-34, 617
  • SEDA-35, 703
  • SEDA-36]
  • Hematologic
  • Liver
  • Leflunomide [SED-15, 2015
  • SEDA-34, 618
  • SEDA-35, 703
  • SEDA-36, 594]
  • Respiratory
  • Skin
  • Genetic Factors
  • Mycophenolic Acid [SED-15, 2402
  • SEDA-34, 622
  • SEDA-35, 704
  • SEDA-36, 594]
  • Systematic Reviews
  • Hematologic
  • Gastrointestinal
  • Lung
  • Drug Formulations
  • Drug-Drug Interactions
  • Sirolimus (Rapamycin) [SED-15, 3148
  • SEDA-34, 626
  • SEDA-35, 705
  • SEDA-36, 594]
  • Systematic Reviews
  • Skin
  • Genetic Factors
  • Drug-Drug Interactions
  • Tacrolimus [SED-15, 3279
  • SEDA-34, 629
  • SEDA-35, 705
  • SEDA-36, 596]
  • Placebo-Controlled Studies
  • Observational Studies
  • Pulmonary
  • Nervous System
  • Endocrine
  • Hematologic
  • Urinary Tract
  • Genetic Factors
  • Drug Formulations
  • Drug-Drug Interactions
  • Temsirolimus [SEDA-34, 632
  • SEDA-35, 707
  • SEDA-36, 597]
  • Systematic Reviews
  • Neuromuscular Function
  • Gastrointestinal
  • Thiopurines [SED-15, 377
  • SEDA-34, 633
  • SEDA-35, 709
  • SEDA-36, 598]
  • Observational Studies
  • Nervous System
  • Ear, Nose, and Throat
  • Hematologic
  • Skin
  • Body Temperature
  • Genetic Factors
  • Drug-Drug Interactions
  • Voclosporin
  • Drug-Drug Interactions
  • Immunoenhancing Drugs
  • Levamisole [SED-15, 2028
  • SEDA-34, 638
  • SEDA-35, 710
  • SEDA-36, 460]
  • Cardiovascular
  • Nervous System
  • Urinary Tract
  • Skin
  • References
  • Chapter 38: Corticotrophins, Corticosteroids, and Prostaglandins
  • Corticotrophins [SED-15, 906
  • SEDA-33, 841
  • SEDA-34, 653
  • SEDA-35, 719
  • SEDA-36, 603]
  • Psychological
  • Endocrine
  • Infection Risk
  • Systemic Glucocorticoids [SED-15, 906
  • SEDA-33, 841
  • SEDA-34, 653
  • SEDA-35, 719
  • SEDA-36, 604]
  • Observational Studies
  • Comparative Studies
  • Systematic Reviews
  • Cardiovascular
  • Nervous System
  • Psychiatric
  • Endocrine
  • Hematologic
  • Gastrointestinal
  • Skin
  • Musculoskeletal
  • Sensory Systems
  • Infection Risk
  • Death
  • Tumorgenicity
  • Drug Interactions
  • Pharmacogenomics
  • Prostaglandins and Analogues [SED-15, 2955
  • SEDA-33, 846
  • SEDA-34, 660
  • SEDA-35, 725]
  • Systematic Reviews
  • Observational Studies
  • Epoprostenol (PGI2)
  • Observational Studies
  • Cardiovascular
  • Drug Formulations
  • Iloprost (PGI2 Analogue) [SED-15, 1716
  • SEDA-33, 847
  • SEDA-34, 660
  • SEDA-35, 726]
  • Comparative Studies
  • Cardiovascular
  • Pulmonary
  • Infection Risk
  • Treprostinil
  • Skin
  • Liver
  • Drug Formulations
  • Drug Administration Routes
  • Latanoprost (PGF2a Analogue) [SED-15, 2002
  • SEDA-33, 847
  • SEDA-34, 660
  • SEDA-35, 726]
  • Misoprostol (PGE1 Analogue) [SED-15, 2357
  • SEDA-33, 847
  • SEDA-34, 660
  • SEDA-35, 726
  • SEDA-36, 612]
  • Systematic Reviews
  • Hematologic
  • Immunologic
  • Fertility
  • References
  • Chapter 39: Sex Hormones and Related Compounds, Including Hormonal Contraceptives
  • Estrogens [SED-15, 1253
  • SEDA-34, 663
  • SEDA-35, 731
  • SEDA-36, 615]
  • Diethylstilbestrol [SED-15, 1119
  • SEDA-34, 665
  • SEDA-35, 731
  • SEDA-36, 615]
  • Reproductive System
  • Second-Generation Effects
  • Hormone Replacement Therapy [SED-15, 1684, 1686, 1692
  • SEDA-34, 666
  • SEDA-35, 732
  • SEDA-36, 616]
  • General Information
  • Hypertension
  • Metabolism
  • Hormonal Contraceptives [SED-15, 1642, 1645
  • SEDA-34, 667
  • SEDA-35, 733
  • SEDA-36, 618]
  • Cardiovascular
  • Thromboembolism
  • Psychiatric
  • Metabolism
  • Hypertriglyceridemia
  • Death
  • Tumorigenicity
  • Emergency Contraception [SEDA-34, 668
  • SEDA-35, 734
  • SEDA-36, 618]
  • Anti-Estrogens and Selective Estrogen Receptor Modulators [SEDA-34, 669
  • SEDA-35, 735
  • SEDA-36, 619]
  • Aromatase Inhibitors [SEDA-35, 735
  • SEDA-36, 619]
  • Anastrazole [SEDA-35, 735
  • SEDA-36, 619]
  • Liver
  • Bazedoxifene Plus CEEs [SEDA-34, 665
  • SEDA-35, 735
  • SEDA-36, 619]
  • Metabolism
  • Exemestane [SEDA-36, 620]
  • Musculoskeletal
  • Raloxifene [SEDA-36, 620]
  • Cardiovascular
  • Tamoxifen [SED-15, 3296
  • SEDA-34, 669
  • SEDA-35, 736
  • SEDA-36, 621]
  • Cardiovascular
  • Tumorigenicity
  • Progestogens [SED-15, 2930
  • SEDA-34, 671
  • SEDA-35, 736
  • SEDA-36, 622]
  • Drospirenone [SEDA-35, 736
  • SEDA-36, 622]
  • Endocrine
  • Etonogestrel [SEDA-36, 622]
  • Respiratory
  • Medroxyprogesterone [SEDA-15, 2225
  • SEDA-35, 737
  • SEDA-36, 623]
  • Infection Risk
  • Progesterone Antagonists [SEDA-34, 671
  • SEDA-35, 738
  • SEDA-36, 625]
  • Mifepristone [SED-15, 2344
  • SEDA-34, 671
  • SEDA-35, 738
  • SEDA-36, 625]
  • Second-Generation Effects
  • Reproductive System
  • Ulipristal [SEDA-36, 626]
  • Reproductive System
  • Anabolic Steroids, Androgens and Related Compounds [SED-15, 216
  • SEDA-34, 672
  • SEDA-35, 738
  • SEDA-36, 627]
  • Anabolic Steroids [SEDA-35, 738
  • SEDA-36, 627]
  • Cardiovascular
  • Urinary Tract
  • Nandrolone
  • Psychological
  • Testosterone [SEDA-35, 739
  • SEDA-36, 628]
  • Tumorigenicity
  • Antiandrogens [SEDA-34, 674
  • SEDA-35, 740
  • SEDA-36, 628]
  • Bicalutamide [SEDA-34, 674
  • SEDA-35, 740
  • SEDA-36, 629]
  • Liver
  • Enzalutamide [SEDA-35, 740
  • SEDA-36, 629]
  • 5a-Reductase Inhibitors
  • Dutasteride SEDA-34, 675
  • SEDA-35, 740
  • SEDA-36, 629]
  • Psychiatric
  • Musculoskeletal
  • Breasts
  • Breast Cancer
  • Leuprolide [SEDA-36, 631]
  • References
  • Chapter 40: Thyroid Hormones, Iodine and Iodides, and Antithyroid Drugs
  • Thyroid Hormones [SED-15, 3409
  • SEDA-31, 687
  • SEDA-32, 763
  • SEDA-33, 881
  • SEDA-34, 679
  • SEDA-35, 747
  • SEDA-36, 635]
  • Eprotirome
  • Hepatotoxicity
  • Levothyroxine
  • Rheumatoid Arthritis (RA)
  • Cardiovascular Disorders
  • Drug Overdose
  • Drug-Drug Interaction
  • Iodine and Iodides [SED-15, 1896
  • SEDA-32, 764
  • SEDA-33, 883
  • SEDA-34, 680
  • SEDA-35, 752
  • SEDA-36]
  • Dietary Iodine
  • Iodine-Containing Solutions
  • Hypothyroidism
  • Iodine-125 Brachytherapy
  • Inflammation
  • Nausea and Vomiting
  • Iodine-131
  • Hypothyroidism
  • Leukopenia
  • Radioactive Iodine
  • Antithyroid Drugs [SEDA-32, 765
  • SEDA-33, 884
  • SEDA-34, 681
  • SEDA-35, 754, SEDA-36, 638]
  • Common Side-Effects
  • Agranulocytosis
  • ANCA-Positive Vasculitis
  • Hepatotoxicity
  • Pancreatitis
  • Teratogenicity and Birth Defects
  • References
  • Chapter 41: Insulin, Other Hypoglycemic Drugs, and Glucagon
  • Glucagon [SEDA-15, 1510
  • SEDA-31, 689
  • SEDA-32, 769
  • SEDA-33, 889
  • SEDA-36, 645]
  • Metabolism
  • Appetite Reduction
  • Insulin [SED-15, 1761
  • SEDA-31, 689
  • SEDA-32, 769
  • SEDA-33, 889
  • SEDA-34, 685
  • SEDA-36, 645]
  • Endocrine
  • Hypoglycemia
  • Nocturnal Hypoglycemia
  • Endocrine
  • Lipotrophy
  • Metabolism
  • Weight Gain
  • Metabolism
  • Appetite Regulation
  • Tumorigenicity
  • Alpha-Glucosidase Inhibitors [SEDA-15, 85
  • SEDA-30, 496
  • SEDA-31, 691
  • SEDA-32, 772
  • SEDA-33, 893
  • SEDA-36, 647]
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Biguanides [SEDA-15, 506
  • SEDA-31, 692
  • SEDA-32, 773
  • SEDA-33, 893
  • SEDA-34, 687
  • SEDA-36, 647]
  • Anti-Tumorigenicity
  • Reduction of Cancer Risk
  • Hepatocellular Carcinoma Benefit
  • Endometrial Cancer Anti-Proliferation Benefit
  • Colorectal Cancer
  • Lung Cancer Reduction
  • Cardiovascular
  • Endothelial Function
  • Dermatology
  • Rosacea-Like Rash
  • Hematology
  • Hemolytic Anemia
  • Nephrology
  • Lactic Acidosis
  • Nutrition
  • Vitamin B12 Deficiency
  • Metabolism
  • Weight Loss
  • Childhood Obesity
  • Reproductive System
  • Endometrial Hyperplasia
  • Teratogenicity
  • Dipeptidyl Peptidase 4 (DDP-4) Inhibitors [SEDA-31, 693
  • SEDA-32, 774
  • SEDA-33, 894
  • SEDA-34, 688
  • SEDA-36, 648]
  • Linagliptin
  • Hepatotoxicity
  • Immunologic
  • Angioedema
  • Musculoskeletal
  • Arthralgia
  • Vertigo
  • Saxagliptin
  • Cardiovascular
  • Heart Failure
  • Sitagliptin
  • Musculoskeletal
  • Achilles Tendonitis
  • Rheumatologic
  • Polyarthritis
  • Vildagliptin
  • Endocrine
  • Hypoglycemia
  • Endocrine
  • Post-Prandial Lipemia and Insulinemia
  • Endocrine
  • Pancreatitis
  • Incretin Mimetic [SEDA-31, 695
  • SEDA-32, 775
  • SEDA-33, 896
  • SEDA-34, 690
  • SEDA-36, 650]
  • Gastrointestinal
  • Nausea, Vomiting, Diarrhea, Dyspepsia
  • Metabolism
  • Appetite Reduction
  • Metabolism
  • Weight Loss
  • Albiglutide
  • Gastrointestinal
  • Dermatology
  • Injection Site Reactions
  • Dulaglutide
  • Cardiovascular
  • Blood Pressure
  • Exenatide
  • Reduction of Infarct
  • Nephrology
  • Acute Interstitial Nephritis
  • Liraglutide
  • Autoimmune Hepatitis
  • Lixisenatide
  • Gastrointestinal
  • Nausea, Vomiting, Diarrhea
  • Pancreatitis
  • Sodium-Glucose Transporter Type 2 (SGLT2) Inhibitors [SEDA-33, 898
  • SEDA-34, 695
  • SEDA-36, 652]
  • Canagliflozin
  • Cardiovascular
  • Blood Pressure Reduction
  • Electrolyte Imbalances
  • Endocrine
  • Hypoglycemia
  • Genitourinary
  • Infections
  • Metabolism
  • Weight Loss
  • Empagliflozin
  • Genitourinary
  • Infections
  • Tofogliflozin
  • Nephrology/Urology
  • Sulphonylureas [SED-15, 3230
  • SEDA-31, 695
  • SEDA-32, 777
  • SEDA-33, 898
  • SEDA-34, 695
  • SEDA-36, 652]
  • Cardiovascular Disease
  • Ischemic Preconditioning
  • Neurology
  • Vascular
  • Thiazolidinediones [SED-15, 3380
  • SEDA-31, 697
  • SEDA-32, 779
  • SEDA-33, 899
  • SEDA-34, 696
  • SEDA-36, 653]
  • Pioglitazone
  • Autoimmune
  • Rheumatoid Arthritis
  • Endocrine
  • Bone Mineral Density
  • Endocrine
  • Inflammation
  • Metabolism
  • Weight Gain
  • Psychiatry
  • Depression
  • Tumorigenicity
  • Rosiglitazone
  • Metabolism
  • Musculoskeletal
  • Thiazolidinediones and HIV/HAART-Associated Lipodystrophy Syndrome
  • Peroxisome Proliferator Activated Dual Receptor Agonists [SEDA-32, 782
  • SEDA-33, 902
  • SEDA-34, 698
  • SEDA-36, 655]
  • Aleglitazar
  • References
  • Chapter 42: Miscellaneous Hormones
  • Introduction
  • Calcitonin [SEDA-34, 703
  • SEDA-35, 789
  • SEDA-36, 659]
  • Clinical Studies
  • Liver Cancer
  • Systematic Reviews and Meta-Analyses
  • Carcinogenic Potential
  • Gonadotropins (Gonadorelin, GnRH and Analogues) [SEDA-35, 789
  • SEDA-36, 660]
  • Prostate Cancer and Chemical Castration Studies
  • Acute Kidney Injury
  • Clinical Studies on Endometriosis
  • Fertility Studies
  • Pediatric Studies
  • Literature Reviews and Meta-Analyses
  • Case Reports
  • Hypertension During Triptorelin in Childhood
  • Pituitary Apoplexy
  • Drug-Induced Rash
  • Traumatic Hematoma
  • Gonadotrophin-Releasing Hormone Antagonists [SEDA-35, 790
  • SEDA-36, 661]
  • Case Reports
  • Ovarian Hyperstimulation Syndrome
  • Special Review - Somatropin (Human Growth Hormone, hGH) [SEDA-35, 791
  • SEDA-36, 661]
  • Cancer Risk in Growth Hormone-Treated Patients
  • Clinical Studies in Adults
  • Stroke Risk
  • Long-Acting Growth Hormone
  • Sustained-Release Growth Hormone
  • Long-Term Safety
  • Pediatric Clinical Studies
  • Central Corneal Thickness
  • Literature Reviews and Meta-Analyses
  • Case Reports
  • Chiari I Malformation
  • Hemangioma Enlargement
  • Growth Hormone Receptor Antagonists [SEDA-34, 708
  • SEDA-35, 792
  • SEDA-36, 664]
  • Clinical Studies
  • Combination Pegvisomant and Somatostatin Analogues
  • Case Reports
  • Type I Hypersensitivity Reaction
  • Melatonin and Analogues [SED-15, 2245
  • SEDA-35, 792
  • SEDA-36, 664]
  • Clinical Studies on Pharmacokinetics and Tolerability
  • Clinical Studies on Sleep Quality
  • Clinical Studies on Anxiety and Depression
  • Other Clinical Studies
  • Literature Reviews and Meta-Analyses
  • Ramelteon
  • Oxytocin and Analogues [SEDA-35, 793
  • SEDA-36, 665]
  • Clinical Studies on Active Labor and Post-Partum Hemorrhage Prevention
  • Clinical Studies on Cardiovascular Effects
  • QT Prolongation
  • Other Clinical Studies
  • Uterine Tachysystole
  • Dose-Escalation Study
  • Literature Reviews and Meta-Analyses
  • Autism Spectrum Disorders
  • Case Reports
  • Oxytocin-Induced Hypoxia
  • Myocardial Ischemia
  • Parathyroid Hormone and Analogues [SEDA-34, 711
  • SEDA-35, 794
  • SEDA-36, 661]
  • Clinical Studies
  • Combination Treatment with Teriperatide and Risedronate
  • Case Reports
  • Calciphylaxis
  • Subungual Exostosis
  • Somatostatin (Growth Hormone Release-Inhibiting Hormone) and Analogues [SED-15, 3160
  • SEDA-35, 794
  • SEDA-36, 666]
  • Lanreotide
  • Clinical Studies
  • Literature Reviews and Meta-Analyses
  • Octreotide and Octreotide Long-Acting Release (LAR)
  • Clinical Studies
  • Polycystic Kidney Disease
  • Systematic Reviews and Meta-Analyses
  • Alopecia
  • Case Reports
  • Head and Neck Paragangliomas
  • Pasireotide
  • Clinical Studies
  • Glucose Metabolism
  • Dumping Syndrome
  • Dose-Limiting Nausea
  • Vasopressin Receptor Antagonists [SEDA-34, 713
  • SEDA-35, 797
  • SEDA-36, 668]
  • Clinical Studies
  • Literature Reviews and Meta-Analyses
  • Vasopressin and Analogues [SEDA-33, 915
  • SEDA-34, 714
  • SEDA-35, 798
  • SEDA-36, 669]
  • Desmopressin (N-Deamino-8-d-Arginine Vasopressin, DDAVP) [SEDA-34, 714
  • SEDA-35, 798
  • SEDA-36, 669]
  • Clinical Studies on Nocturia
  • Pediatric Studies
  • Literature Reviews and Meta-Analyses
  • Case Reports
  • ST-Elevation Myocardial Infarction
  • Diabetes Insipidus Post-Vasopressin
  • Terlipressin [SEDA-34, 714
  • SEDA-35, 798
  • SEDA-36, 669]
  • Clinical Studies
  • Case Reports
  • Prolonged QT
  • Ischemic Bowel Necrosis
  • Severe Hyponatremia
  • Ischemic skin necrosis
  • Vasopressin [SEDA-34, 715
  • SEDA-35, 798
  • SEDA-36, 669]
  • Clinical Studies on Cardiovascular Effects
  • Other Clinical Studies
  • Hyponatremia in Infants
  • References
  • Chapter 43: Drugs that Affect Lipid Metabolism
  • Bile Acid Sequestrants [SED-15, 1902
  • SEDA-36, 676]
  • Cholestyramine
  • Colesevelam
  • Colestipol
  • Cholesteryl Ester Transfer Protein Inhibitors [SEDA-32, 723
  • SEDA-35, 810
  • SEDA-36, 677]
  • Ezetimibe
  • Nicotinic Acid Derivatives [SED-15, 2512
  • SEDA-34, 728
  • SEDA-35, 815
  • SEDA-36, 679]
  • Psychiatric
  • Skin
  • Fibric Acid Derivatives [SED-15, 1358
  • SEDA-32, 804
  • SEDA-333, 922
  • SEDA-34, 724
  • SEDA-35, 812]
  • Gemfibrozil
  • Fenofibrate
  • Urinary Tract
  • HMG-CoA Reductase Inhibitors [SED-15, 1632
  • SEDA-32, 807
  • SEDA-33, 924
  • SEDA-34, 725
  • SEDA-35, 812]
  • Cataracts
  • Diabetes
  • Pancreatitis
  • Exercise
  • Cancer
  • Psychiatric
  • References
  • Chapter 44: Cytostatic Agents
  • Introduction
  • Pyrimidine Analogues
  • Azacitidine (5-Azacitidine)
  • Cardiovascular
  • Infection
  • Gastrointestinal
  • Hematologic
  • Respiratory
  • Skin
  • Fatigue
  • Cytarabine
  • Respiratory
  • Cardiovascular
  • Hematologic
  • Sensory
  • Skin
  • Gastrointestinal
  • Decitabine
  • Cardiovascular
  • Hematologic
  • Infection
  • Skin
  • Gastrointestinal
  • Gemcitabine
  • Cardiovascular
  • Hematologic
  • Thrombotic Microangiopathy
  • Liver
  • Infection
  • Gastrointestinal
  • Pain
  • Immunologic
  • Skin
  • Occular
  • Musculoskeletal
  • Fluoropyrimidines
  • Fluorouracil
  • Hematologic
  • Neurologic
  • Skin
  • Gastrointestinal
  • Cardiovascular
  • Fatigue
  • Capecitabine
  • Skin
  • Hematologic
  • Gastrointestinal
  • Cardiovascular
  • Neurologic
  • Immunologic
  • References
  • Chapter 45: Radiological Contrast Agents and Radiopharmaceuticals
  • Introduction
  • Water-Soluble Intravascular Iodinated Contrast Agents [SEDA-33, 963
  • SEDA-34, 749
  • SEDA-35, 863
  • SEDA-36, 695]
  • Drug Interactions
  • Types of Reactions
  • Salivary Glands
  • Endocrine
  • Cardiovascular
  • Skin
  • Hematologic
  • Immunologic
  • Radiation
  • Iodinated Radiocontrast-Induced Nephropathy
  • Prevalence
  • Prevention
  • Management of Adverse Reactions
  • Susceptibility Factors
  • Diagnosis
  • MRI Contrast Media
  • Gadolinium Salts [SEDA-33, 968
  • SEDA-34, 754
  • SEDA-35, 866
  • SEDA-36, 701]
  • Multiorgan Damage
  • Gadolinium Accumulation
  • Observational Studies
  • Cardiovascular
  • Prevention
  • Superparamagnetic Iron Oxide (SPIO) MRI Contrast Agents [SEDA-33, 970
  • SEDA-34, 757]
  • Ultrasound Contrast Agents [SEDA-32, 855
  • SEDA-33, 971
  • SEDA-34, 758
  • SEDA-35, 869
  • SEDA-36, 703]
  • References
  • Chapter 46: Treatments Used in Complementary and Alternative Medicine
  • Introduction
  • Traditional Chinese Herbal Medicine Preparations
  • Chushizhiyang Paste
  • Qizhengxiaotong Paste
  • Shenqifuzheng Injection
  • Herbal Medicine
  • Green Tea Nutritional Supplements
  • Green Tea Extract
  • Specific Plants
  • Astragali Radix (Huangqi)
  • Luffa echinata (Bristly luffa)
  • Cade Oil
  • Cannabis sativa (Marijuana)
  • Tribulus terrestris (Bulgarian tribulus)
  • Mistletoe Extracts (Viscum album L.)
  • Polygoni Multiflori Radix (Chinese Fleeceflower Root, Heshouwu)
  • Smilacis Glabrae Rhizoma (Tufuling)
  • Acupuncture
  • Cupping
  • Moxibustion
  • Osteopathy
  • Tai Chi
  • Tui Na
  • Yoga
  • References
  • Chapter 47: Miscellaneous Drugs, Materials, Medical Devices and Techniques
  • Aluminum (SEDA-36, 726)
  • Nervous System
  • Long-Term Effects
  • Tumorigenicity
  • Artificial Sweeteners (SED-15, 348
  • SEDA-32, 892
  • SEDA-33, 1011
  • SEDA-35, 786)
  • Metabolic Disorder
  • Long-Term Adverse Health Outcomes
  • Cancer
  • Alteration of Intestinal Microbiota
  • Glucose Intolerance
  • Apoptosis
  • Neurobehavioral Effects
  • Insulin Resistance
  • Benzyl Alcohol (Preservative)
  • Nervous System
  • Calcium (SEDA-36, 727)
  • Mouth and Teeth
  • Catheter (SEDA-36, 728)
  • Urinary Tract
  • Choline (SEDA-36, 728)
  • Cardiovascular
  • Sexual Function
  • Collagen (SEDA-36, 730)
  • Cardiovascular
  • Cremophor
  • Cardiovascular
  • Vitamin D Supplement
  • Dapsone Gel
  • Systemic Toxicity
  • Case report [27A]:
  • Disulfiram (SED-15, 1148
  • SEDA-31, 760
  • SEDA-32, 895
  • SEDA-33, 1016
  • SEDA-34, 791
  • SEDA-36, 731)
  • Neurological
  • Fluoride (SED-15, 1395
  • SEDA-32, 892
  • SEDA-33, 1017
  • SEDA-34, 791
  • SEDA-36, 733)
  • Gelatin (SED-15, 885
  • SEDA-34, 792
  • SEDA-36, 734)
  • Glycine
  • Cardiovascular
  • Water for Irrigation
  • Dietary Glycine
  • Cardiovascular
  • Glycols (SED-15, 1516
  • SEDA-30, 567
  • SEDA-34, 792
  • SEDA-33, 1017)
  • Ethylene Glycol
  • Urinary Tract
  • Propylene Glycol
  • Toxicity in Children
  • Electronic Cigarettes
  • Hyaluronidase
  • Sensory Systems: Eye
  • Hydroxyethyl Starch (SEDA-36, 734)
  • Renal Toxicity
  • Latex (SED-15, 2005
  • SEDA-31, 761
  • SEDA-33, 1018
  • SEDA-34, 792
  • SEDA-36, 736)
  • Immunologic
  • Liposome
  • Dose-Limiting Toxicity
  • Magnesium (SEDA-36, 736)
  • Drug Overdose
  • Drug-Drug Interactions
  • Treatment of Migraine
  • Miltefosine
  • Pancreas
  • Parabens
  • Tumorigenicity
  • Phenol/Phthalate
  • Mutagenicity
  • Sclerotherapy (SED-15, 3107
  • SEDA-33, 1021
  • SEDA-34, 795)
  • Cardiovascular
  • Sevelamer (SEDA-36, 743)
  • Renal Toxicity
  • Silicone oil (Heavy) (SED-15, 3137
  • SEDA-31, 766
  • SEDA-33, 1022
  • SEDA-34, 796
  • SEDA-36, 743)
  • Sensory Systems
  • Talc (SED-15, 3592
  • SEDA-32, 898
  • SEDA-34, 797
  • SEDA-36, 744)
  • Tumorigenicity
  • References
  • Reviewer List
  • Index of Drugs
  • Index of Drug-Drug Interactions
  • Index of Adverse Effects and Adverse Reactions
  • Back Cover

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

320,11 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok